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Abstract 
Development of Novel PLGA Contrast Agents for Use as Ultrasound  
Targeted Drug Delivery Vehicles 
Dalia El-Sherif 
Margaret Wheatley, Ph.D. 
 
 
 
 
Ultrasound is limited in its ability to distinguish between diseased and normal tissue.  
This limitation has led to the development of contrast agents.  We have produced novel 
air-filled microcapsules of poly (lactic-co-glycolic) acid (PLGA/PLA) that work well as 
ultrasound contrast agents.  The agent demonstrated acoustic enhancements up to 24 dB 
in vitro and in vivo.  Furthermore, in vivo Doppler enhancements of a rabbit kidney were 
reported with injections of a 0.1mL/kg dose.  The rabbits did not show any side effects 
from multiple injections (24) of the agent.   
The contrast agent was fabricated by modifying a double emulsion method to 
encapsulate sublimable materials in the oil and aqueous phases.  The encapsulated 
materials were then sublimed, leaving a void in their place.   
The degradation of contrast agents was found to be closely related to both capsule 
morphology and insonation frequency at which they were exposed.  Agent degradation 
was monitored by high performance liquid chromatography (HPLC).  Amounts of lactic 
and glycolic acids produced were quantified.  Glycolic acid repeat units showed a greater 
degradation rate than lactic acid units.  
Additional in vitro studies were carried out to further optimize and characterize the 
agent.  The surfactant solution temperature was found to play an important role in agent 
morphology and acoustic response.  An attenuation study indicated that their resonance 
frequency was ~2 MHz.  Furthermore, in vivo and in vitro studies concluded that the 
  
xviii 
50:50 PLGA agent is temperature sensitive, lasting up to 20 min at 25°C (minimal loss of 
signal (4 dB), while at 37°C the signal drops close to baseline with in the first 5 minutes.  
It was concluded that fabrication of the contrast agent with a more hydrophobic polymer 
extends its acoustic time response.  
Preliminary drug delivery and targeting studies were also investigated. The reported 
results are promising and lay the foundation for future work.   
This research has led to the development of novel PLGA/PLA contrast agents that 
have shown potential use for targeted drug delivery vehicles.  
  
  
1 
1.  INTRODUCTION 
 
 
Diagnosis and treatment of cancer and other devastating diseases have led to the 
investigation of novel imaging and therapeutic systems.  The research presented in this 
thesis is a contribution to a team-based research project based on the development of a 
novel ultrasound targeted drug delivery system.  The long-term team and the thesis 
objectives and scope are described in Sections 1.1 and 1.2, respectively. 
 
1.1 LONG TERM GOALS 
The long-term objective of this research project is to develop a polymer based 
ultrasound (US) contrast agent (CA) with targeted drug delivery capabilities.  In order to 
develop this targeted and imaging drug delivery system, a series of tasks needs to be 
accomplished.  These have been subdivided into four categories (A – D), which are 
outlined below. 
 
A. Physical Characteristics  
The targeted imaging and delivery system must be (1) biocompatible and biodegradable, 
(2) easily transported and stored to be available upon demand for intravenous 
administration prior to imaging, (3) stable after injection for the duration of imaging, (4) 
smaller than 8 mm to pass unimpeded through the capillary system. 
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B. Ultrasound Enhancement 
The targeted imaging and delivery system must be able to (1) enhance the diagnostic 
image (acoustic enhancement ~20 dB) when insonated in the medical imaging frequency 
range (1-15 MHz), and (2) aid the physician in locating diseased tissue. 
 
C. Drug Delivery Properties  
The targeted imaging and delivery system must be able to (1) carry a required amount of 
drug needed to treat a specific condition, (2) deliver the drug within a specified time 
frame, (3) employ ultrasound energy, high (MHz) or low (kHz), to release the “carried” 
drug from the contrast agent, (4) maintain the physical and acoustic characteristics of the 
contrast agent as described above (A: 1-4 and B: 1-2), (5) preserve the stability of the 
drug through the drug loading process, and maintain it until the drug delivery system is 
used.  
 
D. Targeting Properties 
The targeted imaging and delivery system must be able to, (1) carry a “significant 
amount” of targeting molecules. The term “significant amount” is defined as that amount 
which results in maximum adhesion/attachment of the contrast agent to the target cells, 
(2) adhere/attach to target cells in less than three minutes (prior to their 
elimination/destruction) of intravenous injection, and remain attached for the duration of 
imaging and drug delivery, (3) maintain the physical and acoustic characteristics of the 
contrast agent as described above (A: 1-4 and B: 1-2). 
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1.2 THESIS OBJECTIVES 
The main objective of this thesis was to develop a polymer based ultrasound contrast 
agent that has potential for use as a targeted drug delivery vehicle.  The specific aims and 
conditions of the project are listed as follows: 
 
Ø Specific Aim 1: To develop, characterize and optimize a biodegradable polymer 
contrast agent for which at least 95% of the size distribution is less than 8mm.  This 
contrast agent has to meet the requirements described above (A: 1-4 and B: 1).  The 
agent has to be safe for intravenous injection and be able to pass unimpeded through 
the circulatory system, including the pulmonary bed where the capillaries are less 
then 8mm.  The contrast agent has to have a means of being removed from the body, 
hence the choice of a biodegradable material.  The method developed to produce the 
agent has to be repeatable and optimized to achieve an acoustic enhancement of ~20 
dB.  Physical characterization of the contrast agent is to be studied to identify size 
distribution and surface morphology of the capsules.  Cross sections have to be 
obtained to study the interior structure of the capsules.        
 
Ø Specific Aim 2: To achieve in vitro acoustic characterization of the ultrasound 
contrast agent through these two steps: (1) the construction of dose and time response 
curves to determine optimal dose and half-life of the agent, and (2) the comparison of 
dose and time response curves constructed from capsules fabricated with various 
methods to determine the optimal method of development.   
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Ø Specific Aim 3:  To achieve in vivo acoustic characterization of the ultrasound 
contrast agent to determine the in vivo half-life, dose response, and Doppler 
enhancement of the agent.  To ascertain that the contrast agent passes unimpeded 
through both the systemic and pulmonary circulatory systems, and that the animal is 
not distressed (observation by trained medical staff).     
 
Ø Specific Aim 4: To develop a method to characterize the degradation of the 
hollow polymer microcapsules.  To determine the amount of lactic and glycolic acids 
released from the capsules over time.  When these microcapsules are used as drug 
delivery vehicles, understanding their degradation rate is essential in understanding 
the drug release profile.  To investigate the degradation of the agent with and without 
ultrasound (at different frequencies).  It is hypothesized that the capsules will break 
down faster with ultrasound than without and perhaps even faster at one frequency as 
compared to another.  Degradation rate is hypothesized to vary with changes in agent 
morphology.  
 
Ø Specific Aim 5:  To investigate potential use of the agent as a targeted drug 
delivery vehicle.  (1) To carry out preliminary studies of drug adsorption and 
encapsulation, (2) to examine the possibility of attaching targeting molecules on the 
surface of the developed contrast agent, and (3) to fabricate nano capsules by 
considering existing protocols.   
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 2. BACKGROUND AND LITERATURE REVIEW 
 
 
 
This chapter presents background information along with a review of the pertinent 
literature on (1) diagnostic imaging with a focus on ultrasound, (2) microencapsulation 
techniques and drug delivery with a focus on PLGA microcapsules, (3) cancer and (4) 
contrast agents as targeted drug delivery vehicles,. 
 
2.1 DIAGNOSTIC IMAGING 
This section briefly describes the current diagnostic imaging modalities then gives a 
more detailed description of ultrasound as a diagnostic imaging tool and the status of 
ultrasound contrast agents.  
 
2.1.1 Imaging Modalities: Overview 
Currently there are five different imaging modalities, x-ray (including CT), optics, 
nuclear medicine (including PET and SPECT), ultrasound, and MRI that are used for 
medical diagnostic imaging and therapeutic guidance.  
· X-Ray: This modality uses high-energy ionizing radiation, which has some 
harmful effects that are dose dependent.  However, in most cases, the benefits have  
been reported to outweigh the risks.   
· CT [computer (assisted) tomography]: This modality, an expansion of the x-ray 
modality, involves a computerized x-ray technique which acquires cross-sectional 
images through the patient’s body.   
· Nuclear Medicine:  This is an imaging technique wherein small amounts of radio-
isotopes (radioactive substances) are injected into a patient to help trace a disease.  
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Radiation levels are not greater than those used for routine x-ray examinations.  PET 
and SPECT are two techniques of nuclear medicine.  
· PET (Positron Emission Tomography): This imaging technique requires the 
patient to be injected intravenously with a small amount of signal-emitting tracer 
(radio-isotope) tagged to a simple sugar [Ter-Pogossian, 1995].  The PET scanner 
records the signals the tracer emits as it travels throughout the body.  PET can 
differentiate between benign and malignant tumors.  
· SPECT (Single Photon Emission Computed Tomography): This technique 
acquires tomographic slices through the region of interest.  The images acquired are 
based on the concentration of injected radionuclides.  This technique is more complex 
than x-ray and CT because the source of emission is inside the body cavity.  SPECT 
is inferior to PET because of achievable sensitivity and resolution [Jaszczakand et al, 
1995] 
· Ultrasound: This technique employs sound waves with frequencies from 1 to 15 
MHz.  Ultrasound imaging will be described in more detail in the next few sections of 
this chapter.  
· Optical Imaging: This is an imaging technique that uses visible/near infrared 
(NIR) (non-ionizing) light as a technique for diagnostic imaging.  This technique is 
limited in imaging tissues located at greater depths because of the high scattering that 
occurs in cross-sections of biological tissue [Hebden et al., 1997]. 
· MRI (magnetic resonance imaging): This imaging technique is based on the 
absorption and emission of energy in the radio frequency range of the electromagnetic 
spectrum.  
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In determining which imaging modality is to be used, many factors need to be 
considered, some of which are presented here.  
· Patient’s condition: For example, a pregnant woman should not be exposed to the 
ionizing radiation of X-Ray or nuclear medicine and, in such a case, alternate imaging 
modalities would be given priority.  
· Organ to be imaged: For example, when the skull or bowel (gas/air filled) are 
imaged, ultrasound is not an option because of its poor sensitivity. (This concept is 
explained below in more detail.) 
· Tissue location: For example, optical imaging can not be used for imaging an 
organ deep within the body, such as a kidney, because of the depth limitation 
described above.   
· Mobility of the patient: For example, if the patient is in too critical a condition to 
be moved, MRI (a large non-portable machine) may be excluded as an option for 
diagnostic imaging.   
 
The research objective, as outlined in Chapter 1, was focused on therapeutic imaging 
of deep tissue.  The limited depth penetration factor eliminated optical imaging as an 
imaging modality for this application.  Because X-Ray and nuclear medicine expose the 
body to potentially harmful ionizing radiation and injected radioisotopes, respectively, 
these techniques were also eliminated as potential choices for the imaging modalities 
used for this project.  Ultrasound, unlike MRI, is portable and relatively inexpensive, 
which made it the more appealing imaging tool for this project.   
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2.1.2 Ultrasound  
Annually in the United States, more than 30 million ultrasound imaging scans of the 
heart, abdominal organs, and vascular system are performed [Berg, 2001].  While the 
images produced by ultrasound may be sufficient for diagnosing a variety of conditions; 
ultrasound is limited in its ability to distinguish between diseased and normal tissue (for 
example abnormalities in cardiac wall or chambers).  Ultrasound waves travel from the 
exterior of the body, through the body fluid until they hit either a tissue or bone surface.  
At a boundary of two tissues, part of the ultrasound wave is transmitted through the tissue 
and part is reflected back. The amount reflected depends on the impedance mismatch of 
the two tissues.  Acoustic impedance (z) is defined as the product of density (r) and 
speed of sound (c) in a medium, Eq. 2.1 [Kinsler et al., 1982].   
 
Z = r x c           (2.1) 
 
Acoustic impedances for water, air and bone differ from biological tissues, Table 2.1, 
[Shung, 1992]. 
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Table 2.1: Acoustic Impedance Values  
 
 
 
 
 
 
 
Two soft tissue surfaces have similar impedances, and thus the reflection at a soft-
tissue/soft-tissue boundary will be smaller than a soft-tissue/bone or air interface because 
of the large impedance difference between bone and air to soft-tissue [Fisher, 1990].  
This large impedance mismatch can have advantages (increased enhancement of an 
image), or disadvantages (preventing imaging past bone) depending on the tissue and 
imaging location.  
Diseased tissue and healthy tissue have similar acoustic impedances; thus, the 
reflection from that interface will be small, and detection of diseased tissue will be 
difficult.  This contrast limitation has led to the development of contrast agents. 
 
2.1.3 Contrast Agents 
Gramiak and Shah first discovered ultrasound contrast agents in 1968 when they used 
agitated idocyanine green in an aortic root during angiography and found that it produced 
a contrast effect [Gramiak, 1968].  Early contrast agents involved hand-agitated solutions 
[Feigenbaum et al., 1970; Ziskin et al., 1972; Feinstein et al., 1984], which have proven 
Material Impedance (Rayl) 
Water 1.4 
Skull Bone 6.0 
Air 0.000415 
Blood  1.61 
Liver 1.65 
Kidney 1.62 
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to be safe [Bommer et al., 1984].  The air-filled microbubbles contained in the solution 
were shown to be the source of contrast [Ziskin et al., 1972; Meltzer et al., 1980].  While 
free bubbles may work well as contrast agents, they are large and unstable in vivo 
[Wheatley et al., 1999], diffusing into solution in only a matter of seconds.  A shell 
encapsulating the gas bubble will aid in prolonging longevity of the agent.  The shell may 
be composed of protein (Albunex®, Mallincrodt Medical Inc., [Cachard et al., 1996]), 
sugar (Echovist®, Schering, [Pistner et al., 1993]), lipid (SonoVue®, Bracco, [Bokor, 
2000]) or a surfactant (ST68 [Forsberg et al., 1997]), and the gas can be perfluorocarbon, 
sulfur hexafluoride, air or some other inert gas.  Encapsulation of an insoluble 
hydrophobic gas (such as perfluorcarbon) extends the stability of the contrast agent, by 
delaying diffusion of gas out of the microbubble and into the bloodstream.  Contrast 
agents are intravenously injected and enhance the backscattered ultrasound signal from 
the region of interest.  While injecting gas into the blood may seem potentially 
dangerous, it has been shown that in small volumes (200µl) it is not dangerous [Nanda et 
al., 1997].  There are certain requirements that contrast agents need to meet.  The agent 
should not alter the blood flow, should have a size restriction of less than 8 µm to pass 
unimpeded through the capillary circulation, and must be stable enough to perfuse the 
tissue and last the duration of imaging [Jong, 1996] (~3 minutes).  
A contrast agent circulates for a limited amount of time (dependent on the properties 
of the agent).  An end to the contrast effect may be due to one or more reasons.  The 
contrast agent may be destroyed in the process of imaging.  The pressures imposed upon 
it by the body whilst in systemic circulation may also destroy it.  Alternatively, the 
encapsulated air/gas may be diffused out of the agent. Natural processes also play a part 
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in agent elimination.  There is a rapid uptake of intravenously injected particles by the 
cells of the reticuloendothelial system (RES), composed mainly of the kupffer cells of the 
liver and the macrophages of the spleen and bone marrow [Moghimi et al., 1989; Stohik 
et al., 1995].   
Different companies have developed over ten different contrast agents for different 
applications; however, not all have passed the regulatory requirements for use in all 
countries.  Some of these agents are presented here in Table 2.2.  
 
Table 2.2: Examples of Manufactured Ultrasound Contrast Agents  
 
 
 
Company Name Shell/Gas Formulation Application 
Acusphere A1-700 PLGA /Perfluorocarbon  Coronary Artery 
Disease 
Alliance 
Pharmaceutical 
Corp.  
Imagent® Lipid /Perflexane Suboptimal 
Echocardiograms 
Shering Levovist® Galactose and Palmitic 
Acid /Air 
Doppler 
Echocardiography 
Bristol-Myers 
Squibb Medical 
Imaging, Inc.  
DefinityTM Lipid /Octafluoropropane Suboptimal 
Echocardiograms 
Mallinckrodt Optison® Albumin /Perfluorocarbon Diagnosis of Cardiac 
Wall 
Sonus 
Pharmaceuticals, 
Inc.  
Echogen® (No Shell) Perflenapent 
liquid emulsion 
LVO (Left 
ventricular 
opacification) 
Bracco 
Diagnostics, Inc.  
Sonovue® Phospholipid/ Sulphur 
Hexafluoride 
Transpulmonary 
endocardiography/ 
LVO 
Berlex Echogen Galactose Granules/ Air Diagnosis of 
blocked fallopian 
tubes 
  
12 
While the agents presented above are made of different shells, including lipid, 
albumin (protein), and polymer, most of them encapsulate a hydrophobic gas.  The 
hydrophobic gas maintains their stability while in transit through the circulatory system.  
In the case of air-filled Levovist®, the palmitic acid additive maintains this function.  Of 
all the developed contrast agents, only Optison® [Cheng, 1998], Definity™, and most 
recently, Imagent® are FDA (Food and Drug Administration) approved for intravenous 
use in the United States for clinical applications in echocardiography.  While the primary 
goal of these agents is to enhance the diagnostic image, alternate future applications lie in 
targeted drug delivery [Blomley et al., 2001].  Currently, there are no FDA approved 
ultrasound contrast agents that are commercially available for targeted drug delivery.   
 
2.2 MICROENCAPSULATION AND DRUG DELIVERY 
For many years research has focused on the development of novel intravenously 
administered drugs.  Systemic administration of bioactive compounds poses many 
problems, among them are their short in-vivo half lives and their toxic side effects. In 
some cases (such as with cancer treatment), multiple injections of therapeutic agents are 
needed for the required dose to reach the desired target.  While the discovery of novel 
drugs is still a major topic of research, over the past few years, researchers have paid 
great attention to improving drug efficacy by developing new drug delivery systems 
(DDS).  The two major goals of DDS’s are to reduce the total dose of drug and to 
concentrate it at the target site by using “targeting” and “controlled release.”  Drug 
delivery systems are needed to control the location in which drug is deposited and to 
manage the time of drug delivery.  Incorporation of a drug within a biodegradable, 
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biocompatible injectable microsphere has been shown to be a promising approach for 
drug delivery [Ravi, 2000].   
 
2.2.1 Microencapsulation Techniques 
Various techniques, single/double emulsion (solvent evaporation), coacervation, and 
spray drying have been used to manufacture PLGA microspheres [Jain, 2000].  The 
functions and preparation methods of these techniques have been reviewed [Kawaguchi, 
2000].  The outlined advantages of micro particle systems include their small size and 
volume, large specific surface area, high diffusibility and mobility, stable dispersions, 
uniformity and variety.   
Variety can be achieved by varying the method by which the micro particles are 
fabricated.  Methods by which microcapsules can be fabricated are listed and explained 
below:  
· Spray Dry:  The spray dry technique has been widely employed for the fabrication 
of micro particle systems.  It can be applied to heat resistant, heat sensitive, water-
soluble and water insoluble drugs, as well as to hydrophobic and hydrophilic 
polymers.  The technique can be adapted to industrial scale procedures [Giunchedi et 
al., 1995]. 
· Single emulsion (solvent evaporation): The single emulsion technique requires the 
emulsification of an oil phase in a continuous aqueous phase (o/w) or an oil phase 
(o/o) [Watts et al., 1990].  Oil in oil processes tend to be complex techniques 
requiring the removal of oil from the finished product.  This technique may be used to 
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encapsulate hydrophobic drugs in the first oil phase (which is composed of polymer 
and a volatile solvent, such as methylene chloride).    
· Double emulsion (solvent evaporation):  The double emulsion technique requires 
the emulsification of an aqueous solution in an oil phase (w/o), which is then 
emulsified in a continuous aqueous phase (w/o/w) [Watts et al., 1990].  This 
technique may be used to encapsulate a hydrophilic drug in the first water phase or a 
hydrophobic drug in the oil phase.   
· Coacervation:   This technique is a colloid phenomenon [Versic, 1988].  The 
colloid solubility in a solvent solution is reduced by various changes (example pH or 
temperature).  A large part of the colloid is separated out into a new phase.  The 
colloid rich phase coalesces into the coacervate layer, which produces the shell of the 
microcapsule.  Coacervation is a complex technique, (the protocol has been examined 
in detail in published material [Narayan, March 1999]).  
Different fabrication methods result in microcapsules with different properties, 
including size, surface chemistry and texture, morphology, and composition.  Different 
materials also result in chemical and physical changes to the microcapsule system.   
 
2.2.2 Shell Materials  
Many material choices have in the past been investigated for the formulation of 
microcapsules, including, polysaccharides (such as starch, alginate, and agarose), proteins 
(such as gelatin, and albumin), fats and fatty acids (such as palmitic and stearic acid), 
lipids and polymers. 
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Each material has its own benefits with regards to the microcapsule end use and 
application.  Poly lactic-co-glycolic acid (PLGA) has gained tremendous popularity for 
the microencapsulation of therapeutic agents [Smith et al., 1990; Hutchinson et al, 1989].   
 
2.2.3 PLGA [poly (lactic-co-glycolic) acid] 
Poly lactic-co-glycolic acid (PLGA) is a popular biodegradable [Reed, 1981], 
biocompatible [Yamaguchi, 1993] co-polymer.  It has been approved by the food and 
drug administration (FDA) for its use in surgical suture material, VincrylTM and 
Polyglactin 910TM (both composed of 92% glycolic acid and 8% lactic acid), which are 
commercially manufactured and supplied by Ethicon Inc. (a Johnson and Johnson 
company).   
This polymer is composed of recurring lactic and glycolic acid molecules, Fig. 2.1.  
These are two natural body metabolites and produce no toxic effects in the body [Brophy 
et al., 1990; Wu, 1995].  The two acids that make up the copolymer backbone have one 
distinct structural difference.  Lactic acid has an additional bulky methyl group.  The ratio 
of lactic to glycolic acid present in PLGA strongly affects the polymer properties an 
effect that will be discussed later (Sections 2.2.4 and 4.5.5) in more detail.  This polymer 
slowly degrades by non-enzymatic hydrolysis of the ester backbone, into lactic and 
glycolic acids [Gopferich, 1996; Pistner, 1993].   
 
2.2.4 PLGA Microcapsule Degradation  
Various factors affect the degradation pattern of the polymer microspheres, molecular 
weight, co-polymer ratio, microsphere fabrication method, microsphere size, capsule 
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morphology and drug-loading.  The higher the molecular weight of the polymer, the 
longer it will take for the microspheres to degrade.  Microspheres made of a co-polymer 
with high amounts of lactic acid (example PLGA 85:15) will degrade slower then those 
made with a co-polymer of high glycolic acid (example PLGA 50:50) content.  As 
explained in Section 2.2.3, the bulky methyl group of lactic acid makes it more 
hydrophobic than glycolic acid, (thus more difficult for water to get close to a bond 
between two lactic acid molecules), and therefore making it more difficult to break down.  
High energy homogenization, such as probe sonication, is sometimes used to fabricate 
microspheres with a small diameter (1-10mm).  This ultrasound energy has been shown to 
decrease the molecular weight of the polymer [Park, 1994], which will ultimately alter 
the degradation pattern of the formed microspheres [Reich, 1998].  Microcapsule size has 
also been shown to have an effect on degradation rate [Grizzi, 1995].  Although the exact 
mechanism for this is not fully understood, it was hypothesized that the smaller surface 
area cannot accommodate the release of acidic degradation products as well as spheres 
with a larger surface area, resulting in a slower degradation rate.   
Degradation of the co-polymer results in oligomers, dimmers, and monomers of lactic 
and glycolic acid making up the polymer.  Several techniques (gel permeation 
chromatography (GPC) [Reich, 1997], gravimetry [Vert et al., 1991], scanning electron 
microscopy (SEM) [Park, 1994; Park et al., 1995], differential scanning chromatography 
(DSC) [Reich, 1997], and high pressure liquid chromatography (HPLC) [Giunchedi et al., 
1998; Tamanda et al., 1993) have been used to study the degradation of polymer 
microspheres. 
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2.2.5 Encapsulation and Release of Therapeutics from PLGA Microcapsules 
Techniques for fabricating of drug-loaded microcapsules have been studied for over 
two decades [Deasy 1984; Donbrow, 1991].  These techniques (single/double emulsion, 
coacervation and spray drying) have been used for the incorporation of both hydrophilic 
and hydrophobic drugs in PLGA microcapsules.  Most commonly hydrophilic drugs are 
encapsulated through a double, water-oil-water, emulsion process [Yang et al., 2001; 
Blanco et al., 1998] and the hydrophobic drugs are encapsulated through a single, oil-in 
water, emulsion process [Blanco et al., 1998; Oh et al., 1999].  Both methods have shown 
to produce a drug release profile with an initial burst effect (20-80%, dependent on 
experimental parameters including stir speed and surfactant concentration), which is a 
burst of drug immediately when the capsules are suspended in an aqueous solution.  
Elimination or reduction of the initial burst effect has been an area of investigation for 
optimization of the microcapsule drug delivery systems.  One study reported elimination 
of the burst effect by conjugating the drug to PLGA and encapsulating the PLGA-drug 
conjugate [Yang et al., 2001].  This method achieved a zero-order (uniform, no initial 
burst) drug release profile, which took one month to release the encapsulated drug.   
The drug release kinetic rate from PLGA microcapsules is dependent on polymer 
erosion and diffusion of the drug out of the capsules [Lewis, 1990].  Many factors affect 
the release profile of encapsulated drugs.  A higher concentration, larger initial burst and 
faster drug release is seen with a higher drug loading (2.64% as compared to 0.45%) 
[Yang et al., 2001].  High drug loading into a PLGA mold or capsule increases the 
contact between the drug crystals forming channels which an aqueous solution can 
penetrate and diffusion of the drug out of the capsule is facilitated.  The same effects are 
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seen with a decrease in the polymer concentration (16.mg/mL as compared to 
333mg/mL) used to develop drug-loaded microcapsules [Yang et al., 2001; Lambert et 
al., 1995], using less polymer to form capsules of the same size, without altering drug 
loading concentrations, produces capsules that are less dense, facilitating drug diffusion 
out of the system.  To a lesser extent the same effects are noticed with a decrease in 
polymer molecular weight (Mn of 80,000 as compared to Mn of 42,500) [Yang et al., 
2001].  The drug release profile is also related to the degradation properties of the 
polymer.      
    
2.2.6 Ultrasound Induced Drug Delivery  
Various applications of drug delivery by use of ultrasound energy have been reviewed 
[Tachibana et al., 1999; Lindner et al., 2001; Tachibana et al. 2001].  Ultrasound has been 
shown to enhance degradation and drug delivery from biodegradable and non-
biodegradable polymeric devices [Kost et al., 1998; Miyazaki et al., 1988; Kost et al., 
1989].  The mechanism by which ultrasound acts on the degradation and drug delivery 
profiles of the polymeric devices is not yet fully understood; however, it is believed that 
cavitation (Appendix D) may play a role in this effect.   
Various parameters, (ultrasound frequency, size of incorporated drug, and the 
porosity of the polymeric matrices), were investigated and related to the ultrasound 
enhanced drug release effect in a non-biodegradable polymer device [Lavon et al., 1998].  
Almost no enhancement of drug release was seen with high frequency ultrasound, 1 
MHz, while enhancement was observed at a lower frequency of 42 kHz.  Larger drugs 
were released at a slower rate than smaller drugs; this may suggest that ultrasound may 
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work as a mass transport enhancer.  Matrices with micro-pores are more diffusion limited 
and exhibit a pronounced mass transport enhancement compared to those with a macro-
porous structure.       
Low frequency ultrasound, 35kHz, was investigated to enhance the release of drugs 
[Frinking et al., 1998].  The drug release study compared a control (release of 
microencapsulated drug without expose to ultrasound) to an experimental (release of 
microencapsulated drug by exposure to (35kHz) ultrasound) group.  The control group 
released 35% of the encapsulated drug in 120minutes while the experimental group 
released 100% of the encapsulated drug immediately upon insonation.  
Being able to externally control degradation and drug release rates opens many doors 
to non-invasive targeted drug delivery systems. These systems have promising potential 
applications in the treatment of diseases such as cancer. 
 
2.3 CANCER  
Cancer is a disease characterized by the formation of abnormal tissue (neoplasm), 
basically a change in the way cells proliferate and differentiate.  Tumors require the 
development of new blood vessels (angiogenesis) to provide the necessary nutrients and 
oxygen for their expansion.  Contrast agents have been used for tumor visualization.  
Definity microbubbles were shown to enhance visualization of a tumor growing in a 
rabbit thigh [Foster et al., 2000].  Additionally, Foster et al. also discussed the use of high 
frequency (20-100MHz) ultrasound to assess angiogenesis non-invasively, for ocular 
melanoma, malignant melanoma, basal cell carcinoma and Kaposi’s sarcoma.   
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Surgery, radiation therapy, and chemotherapy are currently available treatments for 
cancer.  Local treatments, radiation therapy, and surgery are used in situations in which 
the tumor has not metastasized.  However once the tumor has metastasized, systemic 
treatment, chemotherapy is required [Katzung, 1998], alongside of the local treatment.  
Different anticancer drugs effect different parts of the cell cycle and may have varying 
side effects.  Systemic treatments affect healthy tissue as well as diseased tissue.  For this 
reason, the dose at which the drug is administered is restricted to avoid destruction of 
healthy tissue, this restricts the potential strength that the drug may have on the diseased 
tissue.   
Cancer cells exhibit resistance to multiple structurally dissimilar drugs.  This 
resistance is called “multidrug resistance”, referred to as MDR.  MDR may result in 
treatment failure [Bradley et al., 1998].  Many approaches have been developed to 
overcome MDR.  One mechanism of MDR that has been investigated involves the over 
expression of the transmembrane protein P-glycoprotein (Pgp), which is thought to be 
responsible for drug efflux [Robinson et al., 1987]. One approach to prevent resistance is 
to protect the drug against the pumping action of Pgp.  This protection can be 
accomplished by two means: the drug structure can be chemically modified, and/or the 
drug can be associated to a drug carrier.   
Anticancer drugs encapsulated within liposome carriers have been shown to reduce 
the toxic effects and enhance the therapeutic effects in animal tumor models [Olson et al., 
1982; Mayhew et al., 1983; Gabizon et al., 1985; Szoka et al., 1991].   
Localized delivery of anticancer drugs is essential for the preservation of normal cells 
and for a strong toxic effect against the infected tissue.  Localized delivery allows for the 
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administration of the drug in high doses, having a much stronger effect on the region of 
interest than systemic administration.  Localized delivery is an efficient and cost effective 
method of delivering a drug; less of the agent is needed for a stronger effect.  Ideally, the 
drug delivery system should have a minimal initial burst effect and be able to deliver the 
drug to the desired location within hours.  
 
2.3.1 Anticancer Agents  
2.3.1.1 Doxorubicin (Adriamycin) 
Doxorubicin (adriamycin), Fig. 2.2, is an anthracycline antibiotic isolated from 
streptomyces peucatius var caesius.  It is a water-soluble drug [Katzung, 1998].  
Doxorubicin works by interfering with cell replication by binding to DNA through 
intercalation between specific bases and blocks the synthesis of new RNA and/or DNA, 
causing DNA strand scission.  
Anthracycline doxorubicin is used in the treatment of solid tumors.  Its usefulness, 
however, is limited in its side effects.  Systemic administration of doxorubicin has acute 
side effects including nausea and red urine (not hematuria) and delayed toxic effects 
including bone marrow depression, chronic cumulative dose limiting cardiac toxicity, 
alopecia and stomatitis and the development of resistance [Blum et al., 1974; Kessel et al. 
1988; Unverferth et al., 1982].  These effects are seen even with the controlled low doses 
(60 mg/m2 IV over 3 weeks to a maximum dose of 550 mg/m2) of the drug [Katzung, 
1998].    
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2.3.1.2 Paclitaxel (Taxol) 
Paclitaxel (Fig. 2.3), a relatively new anticancer drug, has been used for the treatment 
and management of cancer, despite problems associated with its hydrophobic nature.  
Paclitaxel is extracted from the Pacific yew tree, which is one of eight varieties of taxus 
from the species Taxus Brevifolia [Virginia, 1993]. The development of paciltaxel as an 
anticancer drug dates back to the Celts, who used the yew tree’s sap as poison on their 
arrow tips and the american indians who used the tree for medicinal purposes, boiling its 
bark, and using it for the treatment of respiratory problems [Nakasami, 1992].    In the 
1950s and 1960s, the National Cancer Institute starting testing products of the yew tree 
for cytotoxic activity [Song et al., 1991; Robinson, 1991]. In the 1970s, the active 
ingredient of the yew tree was identified [Wani et al., 1971] and in 1979, the mechanism 
of action was discovered: Paclitaxel works by promoting microtubule assembly [Schiff et 
al., 1979; Schiff et al., 1980].  Microtubules are long, hollow structures that form the 
mitotic spindle on which the chromosomes move during mitosis and provide the means 
for transport of vesicles, organelles, and mitochondria [Ganong, 1999].  Paclitaxel binds 
to microtubules, making them so stable that various organelles cannot bind to them nor 
can mitotic spindles form, leading to cell death [Rowinsky et al., 1990].  Paclitaxel has 
antiproliferative, antiangiogenic [Kluber et al., 1997], antimetastatic [Sreans et al., 1992] 
and apoptotic [Yen et al. 1996] properties.    
Systemic administration of paclitaxel has acute side effects, including nausea, 
vomiting, hypertension, and arrythmias, and delayed side effects, including bone marrow 
suppression.  These effects are seen even with the controlled low doses (130-170 mg/m2 
IV over 3 weeks or 24 hours every 3-4 weeks) of the drug [Katzung, 1998].   
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2.3.1.3 Controlled Delivery of Paclitaxel and Doxorubicin 
Various systems (microspheres, surgical pastes, and biodegradable implants) have 
been investigated for the localized delivery of Paclitaxel [Dhanikula et al., 1999].    The 
encapsulation of paclitaxel within solid PCL (poly (e-carpolactone)) [Dordunoo, 1995] 
and PLGA [Wang et al., 1996] microcapsules has been investigated.  Both methods 
resulted in a very slow drug delivery system (within weeks) and had an initial burst effect 
(~15%).  Encapsulation of the drug within PLGA microcapsules causes slow delivery of 
the drug through diffusion and polymer erosion [Lewis, 1990].  
A drug delivery study with doxorubicin reported that loading efficiency was much 
greater (99.09%) when the doxorubicin was conjugated to a di-block co-polymer of 
PLGA-PEG (poly lactic glycolic acid  - poly ethylene glycol), than when it was 
physically entrapped within the copolymer (23.18%).  Release profiles were also very 
different, yielding 100% release of the entrapped drug after 4 days and only about 60% of 
the conjugated drug after 15 days [Yoo et al., 2001].   
In another study doxorubicin was chemically conjugated to a terminal end group of 
PLGA by an ester linkage and the conjugated Dox-PLGA was incorporated into nano 
particles and compared to incorporated free doxorubicin.   A sustained release profile of 
up to one month was seen with the conjugated drug compared to the 5 day release profile 
seen with the free drug [Yoo et al., 2000]. 
 
2.3.2 Nano Applications and Targeting 
One of the promising applications of nano particles is their use as carriers for 
anticancer agents [Labhasetwar et al., 1997].  Intravenously administered nanoparticles 
  
24 
tend to extravasate at pathological sites, such as solid tumors by passing through the 
leaky tumor vasculature (passive targeting).  Polymeric micelles (about 50nm) were 
reported to enhance vascular permeability [Kwon et al. 1996].  Nanoscopic drug carriers 
evade recognition and uptake by the macrophages of the liver and spleen and circulate for 
prolonged periods of time [Gref et al., 1995].   In one study anticancer agent Paclitaxel 
was incorporated into polyvinylpyrrolidone nanospheres (50-60nm) and intravenously 
injected into mice, and compared to a control group (mice which received free Paclitaxel) 
[Sharma et al., 1996].  There was a significant tumor regression and higher survival rate 
in the mice that received the paclitaxel-loaded nanospheres. 
There is, however, a trade-off between the use of nano versus micro scale particles, in 
that the nano particles cannot accommodate as much drug payload as the micro particles.  
Thus, more nano particles than microparticels will be required for injection to achieve the 
same drug dose.   
Researchers at many academic and industrial institutions have been investigating the 
concept of targeting drug delivery systems to various diseased tissues.  There are several 
areas of interest with respect to tumor targeting, two of which are described below.  
One is the concept of making the drug delivery system “invisible” to the macrophages 
(these modified systems are called Stealth technology) [Storm et al., 1995].  This concept 
allows the particles to circulate for a longer period of time once injected.  This in turn 
allows them to selectively extravasate in diseased sites, like tumors and inflammation 
sites where the vasculature is leaky [Moghimi et al, 2001].  Alza Corporation’s liposomal 
StealthÒ technology, example of this concept, has shown promising results in 
encapsulating doxorubicin and recirculating systemically for days without releasing the 
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drug until it has penetrated into the tumor [An Alza Technology Publication, Delivery 
Times, Volume II, Issue I].  The Stealth liposomes have a unique PEG (polyethylene 
glycol) coating that reduces mononuclear phagocyte system (MPS) uptake.  They have a 
diameter of approximately 100nm, which is large enough to carry a substantial drug load 
but small enough to allow efficient extravasation through leaky tumor vasculature.  
The second concept revolves around targeting the blood vessels of pathological 
lesions.  Vasculature of diseased tissues, such as tumors, has their own signatures 
[Ruoslahti, 2000]. Endothelial cells in the angiogenic vessels of solid tumors express 
proteins that are not expressed or are not detectable in normal blood vessels [Ruoslahti, 
2002].  Because tumor vasculature is different from normal vasculature it may be 
selectively destroyed with minimal harm to normal vasculature.  Research has been 
ongoing to identify antibodies and peptides that recognize these vascular signatures and 
can be used to target drug selectively to them.  Tumor vasculature was found to over 
express the cell adhesion receptors, integrins avb1, avb5 and avb3 [Eliceiri et al., 1999; 
Kim et al., 2000].  In one study, integrins avb5 and avb3 sites have been used to target 
anticancer drugs selectively to tumors.  Doxorubicin was coupled to peptides that home 
specifically to tumor blood vessels [Arap et al., 1998].  Results showed enhanced 
efficiency of the drug against human breast cancer xenografts in nude mice.   
 
2.4 CONTRAST AGENTS AS TARGETED DRUG DELIVERY VEHICLES 
Use of ultrasound to externally control drug delivery coupled with the ideal situation 
of monitoring exact location of drug deposit led to the investigative use of ultrasound 
contrast agents as drug delivery systems.   
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ImaRax Therapeutics, Inc., the original developer of DefinityTM, is a key player in the 
field of targeted ultrasound contrast agents, and has been granted several patents specific 
to this area of research [Unger et al., 2003; Matsunaga et al., 2002].  ImaRx has 
investigated the development of acoustically active microbubbles that bind or entrap 
genetic material onto the surface of the agents for cell-specific delivery [Unger et al., 
2001].  ImaRx explains that, while microbubbles have been around for several decades, 
their therapeutic applications are in their infancy [Unger et al., 2002].   
Cav-Con, Inc., another industry player in the area of targeted therapeutic imaging, has 
been adapting their lipid coated microbubble (LCM), FlimixÒ, for targeted drug delivery.  
They have reported the LCM product to be successful in detection and diagnosis of 
experimental tumors in rat brains [D’Arrigo et al., 1991; Simon et al., 1992] and liver 
[D’Arrigo et al., 1993].  Additionally it was confirmed that the LCM agent had an 
accumulation within the tumor mass.  These researchers have also investigated the use of 
the lipid-coated microbubbles for targeting the anticancer agent Paclitaxel [Ho et al., 
1997].  
Mallincrodt, the manufacturer of OptisonÒ, has also shown targeted capabilities of 
lipid-coated microbubbles, by attachment of specific ligands to the agent allowing it to 
bind to targeted locations [Kilbanov et al., 1999].    
 
2.5 THESIS OVERVIEW 
This thesis discusses the development of a novel PLGA/PLA ultrasound contrast 
agent for potential use as a targeted drug delivery vehicle. In designing a contrast agent 
for therapeutic use, the material of which the shell is composed is critical.  Polymeric 
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microcapsules have many advantages: they are stable, they provide a good surface to 
adsorb or carry the drug, and they have good shelf life stability.  
Our laboratory has produced hollow PLGA microspheres using adaptations of solvent 
evaporation, coacervation, and spray drying methods.  These methods involved 
encapsulation of a solid volatile core material, ammonium carbonate, which was later 
removed by sublimation [Narayan et al., 1999; Narayan et al., 2001].   
Grinding the solid core material presented challenges.  Testing and analysis of the 
method were performed and are discussed (Section 4.1.1).  Limitations associated with 
these microcapsules (fabricated by encapsulating a solid core material) have led to the 
development of novel methods for fabrication of a PLGA/PLA contrast agent.  These 
novel methods involved encapsulation of dissolved sublimable material through adapted 
and modified double emulsion methods.  Initially water droplets were encapsulated and 
sublimed producing Native agent (Section 4.1.2).  The method used to fabricate Native 
agent was modified to increase backscatter enhancement, and produce Phase I and Phase 
II contrast agents (Section 4.1.3).  The modifications involved encapsulating and 
subliming dissolved camphor and ammonium carbonate.  The surface (Section 4.1.3.2.1) 
and internal morphologies (Section 4.2) of the agent have been studied.  Additionally 
degradation of the agent was traced via an HPLC (high pressure liquid chromatography) 
method (Section 4.3).  In vivo studies were carried out at Thomas Jefferson University 
Hospital (Section 4.5).  Results from in vivo experimentation were unexpected and led to 
further characterization and optimization of the contrast agent (Section 4.5).  
Experimental methods pertinent to microcapsule fabrication and characterization are 
discussed in chapter 3 and a list of materials is presented in Appendix A.  
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Preliminary targeting and drug delivery experiments were carried out to test the 
potential use of the agents as targeted drug delivery vehicles (Chapter 5).  Materials and 
methods pertinent to targeting and drug delivery are also discussed (Chapter 5).  
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Figure 2.1: Structure of Poly (lactic-co-glycolic) acid (PLGA) 
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Figure 2.2: Structure of Doxorubicin (Adriamycin) 
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Figure 2.3: Structure of Paclitaxel (Taxol)
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 3.  EXPERIMENTAL METHODS  
(CONTRAST AGENT FORMULATION AND ANALYSIS) 
 
 
 
A thorough description of the methods and the related critical factors are presented 
for each relevant protocol required for the experiments described within this chapter. 
These methods pertain to the development and characterization of a novel polymeric 
ultrasound contrast agent.  For a detailed discussion pertaining to agent fabrication 
reference to chapter 4 is required. All methods related to drug delivery, targeting and 
nano particle fabrication are described later in Chapter 5.  A list of materials used is 
presented in Appendix A.    
   
3.1 POLYMER HANDLING AND STORAGE 
Proper handling and storage of the polymer is important to avoid the degradation of 
the polymer and any changes in results due to this effect.  Exposure of the polymer to 
moisture will result in its degradation.  All steps outlined below ensure minimal exposure 
of the polymer to moisture and have therefore resulted in consistent experimental 
outcomes.     
The polymer (stock) package purchased from Alkermes was immediately stored 
(sealed) in a freezer upon arrival.  When needed, the sealed stock was taken out of the 
freezer, allowed to reach room temperature and then opened; small aliquots were taken 
out and placed in 20mL glass vials for everyday use.  The polymer stock package was 
sealed with tape, placed in a plastic container, which was wrapped with parafilm and 
stored in the freezer.  The glass vials were tightly sealed with a screw cap, wrapped in 
parafilm to avoid exposure of the polymer to moisture, and stored in a 4°C refrigerator.  
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When needed a glass vial was taken out of the refrigerator and placed on the bench top, 
fifteen minutes were allotted to ensure that the vial and its polymer content reach room 
temperature.  The screw cap was removed, the polymer needed was weighed out, and the 
screw cap was immediately replaced and tightened.  The glass vial was again wrapped in 
parafilm and placed back in the refrigerator.   
This method of separating a polymer aliquot from the stock for everyday use, allows 
the stock to be stored sealed in the freezer, for months to a year, and avoids its constant 
exposure to the air.  The small aliquots are generally used within one to two months and 
their minimal exposure to moisture for that time frame has not shown to have any effect 
on the results obtained (based on SEM (scanning electron microscopy) analysis of 
fabricated microcapsules).   
Storage of the polymer aliquots in a desiccator, however, would also aid in protecting 
the stored polymer from degradation.   
 
3.2 AGENT FABRICATION 
Three methods were investigated to develop polymeric contrast agents.  First, a 
double emulsion method was adapted to encapsulate and sublime water droplets, 
microcapsules produced by this method were named Native agent.  Second, the adapted 
double emulsion method was further modified to encapsulate a second sublimable core 
material, microcapsules produced by this method were named Phase I agent.  Finally, the 
double emulsion method was again modified to encapsulate a third sublimable core 
material, microcapsules produced by this method were named Phase II agent.  The 
methods by which the Native, Phase I and Phase II agents were fabricated are described 
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next (in Sections 3.2.1, 3.2.2 and 3.2.2, respectively).  A discussion of the critical aspects 
that are related to the fabrication processes is also presented.  Critical aspects that pertain 
to more than one fabrication method are described only once but referred to as necessary.  
Additionally previously modified [Narayan, March 1999] solvent extract and 
coacervation methods are also briefly described in Sections 3.2.4 and 3.2.5, respectively.  
Microcapsules were fabricated by these methods for analysis and comparison to Native, 
Phase I and Phase II agents.    
 
3.2.1 Native Agent by Double Emulsion 
Native agent was fabricated by an adapted double emulsion (W/O)/W solvent 
evaporation process.  Fabrication of Native agent was carried out to establish a platform 
on which all future microencapsulation experiments would be based.  Native agent would 
have to meet certain requirements including a uniform size distribution of less than 8mm 
and exhibit no aggregation tendencies when suspended in an aqueous medium.  A 
summarized schematic representation of this fabrication method is provided in Appendix 
B (Fig B.1).   
For best results, efficiency and sufficient time management in microcapsule 
fabrication the following order of steps was followed and is recommended. 
 
Preparation (pre-fabrication of agent):  
1 - The polyvinyl alcohol (PVA) solution (50mL) was placed in a 400mL beaker, covered 
with parafilm and stored in a refrigerator (4°C) until needed.  (A 400mL beaker is 
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required because homogenization takes place during the fabrication process and causes 
the surfactant solution to foam.  A smaller beaker will cause the solution to overflow).  
· PVA ([-CH2-CHOH-]n ) is a completely water soluble polymer that may act as a 
surfactant.  A surfactant by definition is a soluble compound that reduces the 
surface tension of liquids. 
· PVA Preparation – A 5w/v% of PVA solution was prepared at least 24 hours prior 
to microcapsule fabrication.  Preparation of PVA solution is somewhat time 
consuming.  It was found that the preparation of large volumes (500mL) at one 
time was the most practical.  PVA was weighed (25g) and dissolved in 500ml of 
deionized water (this volume will make up to 5 batches of microcapsules).   
· The deionized water was heated (~40-45°C) prior to dissolving the PVA.  A 
vortex was created at maximum stir/bar speed prior to placing the PVA in the 
beaker.  Small amounts (1/5) of the PVA were dissolved at a time, until the entire 
25g were added.  Placing all the PVA in the water at once will cause it to settle, 
adhering to the stir bar and making it difficult to dissolve.   
· Once fully dissolved (about two hours) the warm PVA was filtered through a 
0.45mm bottle top filter into a glass bottle.  The bottle screw cap was securely 
tightened and the PVA was stored in the refrigerator.  (Maintaining a cold (4°C) 
PVA temperature is important as is has shown to have an effect on microcapsule 
fabrication (Chapter 4)).  
· Maintaining the 5w/v % PVA solution is critical to repeatability of microcapsule 
morphology.  Decreasing the w/v% (within a limit of 2.5w/v %) has been shown 
to fabricate larger size microcapsules [Kwon et al, 2001].   
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2 - The polymer was weighed (0.5g) in a small weigh dish, covered with parafilm and 
placed aside.  
· Polymer here refers to 50:50 PLGA, 75:25 PLGA, 85:15 PLGA or PLA.  The 
polymer used is identified for each experiment.   
· The amount of polymer should remain constant, scaling up is not a straight 
forward process, and increasing the amount of polymer will result in changes in 
microcapsule size and morphology.  (Increasing polymer weights up to 2.5g was 
attempted and based on SEM analysis 0.5g  yielded the most uniform 
microcapsules with the required size distribution).  
 
Fabrication Process:  
Step A: 
Methylene chloride (10mL) was placed in a 50mL beaker and immediately covered with 
2 layers of parafilm.   
· Methylene chloride evaporates fast and changes in volume can occur within a few 
minutes.  The amount of methylene chloride should remain constant for 
repeatability of microcapsule size and morphology, and covering with parafilm, if 
it is not to be used immediately, will assure that.   
 
Step B: 
The polymer (0.5 g) was placed in the methylene chloride, covered with parafilm and 
stirred until fully dissolved.   
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· A vortex was created at maximum stir/bar speed, to avoid settling and sticking of 
the polymer to the stir bar when it was placed in the methylene chloride. Settling 
will make this polymer difficult to dissolve.  
· The polymer/methylene chloride solution was covered with parafilm to avoid 
evaporation of the methylene chloride and to maintain the initial concentration.  
· Keeping the concentration constant is required to maintain the consistency of 
microcapsule fabrication.  Changes in this will result in size variations and 
perhaps even morphology changes in the produced microcapsules.   
 
Step C: 
To generate the first (W/O) emulsion, the stir bar was removed from the polymer solution 
beaker, 1.0 mL of deionized water was added to the solution and probe sonicated (using a 
XL-series, Misonix Incorporated sonicator) at 110 Watts for 30 seconds.   
 
Step D - E: 
The PVA solution was taken out of the refrigerator and the parafilm covering was 
removed.  The (W/O) emulsion was then immediately poured into the PVA solution and 
homogenized (using PT-3100 Homogenizer, Brinkmann Instruments, with a 
PTDA3020/2 sawtooth blade) for 5 minutes at 9,500 rmp.  
· The PVA acts as a surfactant and reduces the surface tension, while simultaneous 
homogenization breaks the W/O emulsion into a population of small drops.   
· The 50mL beaker was washed while the W/O emulsion was being homogenized 
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· A thin film of polymer is left behind in the 50mL beaker when the 
polymer/methylene chloride solution is poured into the PVA solution, this should 
be removed immediately before allowing it to dry.  Attempting to remove/wash 
the polymer solution from the beaker once it has dried is difficult and time 
consuming.  
· This thin film accounts for some of the loss in the yield. 
 
Step F: 
A 100mL solution of 2% isopropanol solution was then poured into the 400mL beaker 
with the homogenized solution, and stirred for 1 hour at room temperature.  
· Evaporation of the methylene chloride takes place during this phase of the 
fabrication process, hardening the capsules.  
Step G: 
The capsules were collected by centrifugation 
· The stirred solution was divided into 4-6 centrifuge tubes, and centrifuged at 15°C 
for 5 minutes at 5000xg. 
· The supernatant was carefully discarded from each centrifuge tube.  The 
supernatant should be removed immediately when the centrifugation time is 
complete, allowing the centrifuge tubes to sit for a while prior to removing the 
supernatant will cause the pellet of microcapsules to start dispersing in the 
deionized water, resulting in loss of microcapsules and lowering the yield.  
· The microcapsule pellets from the 4-6 centrifuge tubes were collected into one 
centrifuge tube.  To assure complete collection of the microcapsules and reduce 
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possible loss, capsules adhering to the tube walls were washed into the collecting 
tube with 2x3mL of wash each.  Deionized water was added to the collecting tube 
to bring the total volume up to 45-50mL. The microcapsules were centrifuged 
again (at 15°C for 5 minutes at 5000xg) and the supernatant discarded.   
 
The capsules were then washed three times with hexane (about 10mL per wash) to further 
extract the methylene chloride from the polymer beads.   
· Hexane was added to the centrifuge tube and the pellet was broken up and 
manually stirred with a metal spatula.  The hexane was removed with a pipette 
between each wash.  Initially the pellet was hard, sticky and difficult to stir.  By 
the end of the hexane wash phase the microcapsules were well dispersed within 
the hexane and the solution had a foamy appearance to it.   
· After the last hexane, wash the capsules were left under the hood for half and hour 
to allow excess hexane (that which could not be removed with a pipette) to 
evaporate.   
Deionized water was added to the microcapsules in the centrifuge tube (for a total volume 
of 45-50mL), centrifuged for 5 minutes at 5,000xg, and the water discarded.  
About 1-3mL of deionized water was added to the microcapsule pellet.  To 
produce dry “fluffy” microcapsules that can be easily suspended in an aqueous solution 
the microcapsule pellet was broken up and suspended in the deionized water with a metal 
spatula.  The capsules were frozen in a -85ºC freezer and lyophilized, using a Virtis 
Benchtop freeze dryer, to fully dry the capsules and sublime the encapsulated water.  
Freeze drying time is dependent on the total amount of water volume in the centrifuge 
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tube (total amount by the end of this phase in the fabrication process is estimated to be no 
more than 10mL).  The capsules were lyophilized for ~48 hours.   
The dried microcapsules were weighed into a 20mL glass vial, the vial screw cap 
was tightened, wrapped in parafilm, and the vial was stored in a 4°C refrigerator.  Percent 
yield was calculated. 
 
3.2.2 Phase I Agent by Encapsulation of One (Non-Water Soluble) Sublimable Core 
Material 
 
Phase I agent was prepared by modification of the double emulsion (W/O)/W solvent 
evaporation process used to fabricate Native agent (Section 3.2.2.1).  A schematic 
representation of this method is provided, Appendix B, Fig B.2.  Only one addition was 
made to the microcapsule fabrication process (in an attempt to increase the acoustic 
enhancement process), which is presented below.  For thorough understanding of the 
process, reference to Section 3.2.2.1 is required.   
 
Modification of Step B of  Native Agent Fabrication Process: 
Camphor is a hydrophobic substance and is encapsulated in the oil phase. 
· The camphor was weighed (0.05g) in a small weigh dish, covered with parafilm 
and placed aside. 
· The amount of camphor relative to polymer should remain constant. Increases or 
decreases in the amount of camphor were shown to reduce the acoustic 
enhancement properties of the microcapsules, (section 4.1.3.1).   
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· The camphor was dissolved in the methylene chloride prior to addition of the 
polymer. 
 
 
The microcapsule fabrication process used to fabricate Native agent was then 
followed.  This modified method produces microcapsules of mixed camphor and polymer 
prior to lyophilization.  Camphor and water sublime when freeze dried, leaving a void in 
their place. 
 
3.2.3 Phase II Agent by Encapsulation of Two Sublimable (Water and Non-Water 
Soluble) Core Materials 
 
Microcapsules were prepared by modification of the double emulsion (W/O)/W 
solvent evaporation process used to fabricate Phase I agent, a summarized schematic 
representation of this method is provided, Appendix B, Fig B.3.  Only one addition was 
made to the microcapsule fabrication process, (in an attempt to further increase acoustic 
enhancement), which is presented below.  For thorough description and understanding of 
the process, reference to sections 3.2.2.1 and 3.2.2.2 is required.   
 
Modification of Step C of Phase I Agent Fabrication Process: 
Ammonium carbonate is a hydrophilic substance and is encapsulated in the water phase.   
· Preparation of 4w/v% ammonium carbonate solution: The ammonium carbonate 
solution was prepared while the polymer was dissolving in the solvent.  Although 
only a 1mL solution is required per microcapsule batch, a 10mL solution was 
prepared to avoid errors related to working with small quantities.   
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· Ammonium carbonate (0.4g) was weighed and dissolved in 10ml of deionized 
water (This volume will make up to 10 batches of microcapsules).   
· Ammonium carbonate should not be prepared more than 30 minutes prior to use 
in the microcapsule fabrication process.  This has been tested and will affect the 
acoustic enhancement properties of the fabricated microcapsules (will result in 
lower enhancements).   
 
The rest of the method of producing Phase I contrast agent was not altered (this 
included methods used to fabricate Native agent).  Microcapsules of mixed polymer, 
camphor, and ammonium carbonate were produced prior to freeze drying.  Camphor, 
water, and ammonium carbonate sublime when freeze dried and leave a void in their 
place.  
 
3.2.4 Solvent Extraction – Encapsulating Solid Ammonium Carbonate  
 For analysis and comparison of previous methods, microcapsules were fabricated by a 
modified solvent extraction method [Narayan, March 1999].  Briefly, PLGA (1g 
RG504H) was dissolved in 20mL of Acetonitrile.  Ground ammonium carbonate (1g) 
was suspended in the solvent.  Mineral oil (200mL) with suspended Span 80 (4g) was 
prepared and homogenized.  The acetonitrile mixture was slowly pipetted into the oil as it 
was continuously homogenized.  After complete addition of the acetonitrile mixture the 
sample was homogenized at 18,000rpm for 30minutes.  The homogenized oil was poured 
into 800mL of hexane and stirred for two hours.  The mixture was allowed to settle for 24 
hours under the hood, after which it was filtered.  The filtered sample was freeze dried.   
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3.2.5 Coacervation – Encapsulating Solid Ammonium Carbonate 
For analysis and comparison of previous methods, microcapsules were fabricated by a 
modified coacervation method, Section 2.2.1 [Narayan, March 1999].  Briefly, PLGA 
(1.59g of RG504H) was dissolved in 60mL of methylene chloride.  Ammonium 
carbonate (1.6g) was suspended in the solvent.  The suspension was slowly added to 
33mL of silicone oil, and homogenized for 3min at 18,000rpm.  The homogenized 
sample was poured into 800mL of hexane with 3 drops of Span 80, and stirred for 1 hour.  
The sample was filtered and the collected microcapsules freeze dried.   
 
3.3 ACOUSTIC STUDIES 
In vitro (attenuation, dose and time response) and in vivo (dose and time response) 
acoustic studies were carried out.  Sections 3.3.1 and 3.3.2, explain the methods and 
parameters employed for these in vitro and in vivo experiments, respectively.   
 
3.3.1 In Vitro Acoustic Testing 
For all in vitro acoustic studies, a one-dimensional pulsed A-mode ultrasound set-up 
was used with one of five single element broadband, 12.7mm element diameter, 50.8mm 
spherically focused transducers (Panametrics, Inc., Waltham, MA).  The parameters of 
the transducers, as provided by the vendor, are summarized in Table 3.1.   
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Table 3.1: Parameters of Transducers Used for in Vitro Experimentation 
 
 
Transducer  2.25 5 7.5 10 15 
Serial Number 236834 228153 255112 228185 237135 
Model V-306 V-309 V-320 V-311 V-319 
Center Frequency (MHz) 2.31 5.45 7.6 9.8 14.5 
Peak Frequency (MHz) 2.53 6.4 7.65 10.7 14.5 
(-6dB) Bandwidth % 89.18 91.74 60.53 65.31 51.03 
Spectrum Range (Low) MHz 1.28 2.95 5.3 6.6 10.8 
Spectrum Range (High) MHz 3.34 7.95 9.9 10.7 18.2 
 
 
 
The pulse lengths of the transducers were calculated by equation 3.1 (Panametrics, 
Waltham, MA).  
Pulse Length = Number of Periods*Wavelength     (3.1) 
Where: 
Number of Periods is taken (approximated) from the oscilloscope 
Wavelength (l)(mm) = speed of sound (c)/ frequency (f)  
Speed of sound in water was taken as 1500m/s and repetition rate was set at 100Hz 
 
Table 3.2: Pulse Length Calculations 
 
 
Transducer  2.25 5 7.5 10 15 
Number of Periods  ~ 2 ~ 4 ~ 5 ~ 5 ~ 4 
Wavelength (mm)  0.67 0.3 0.2 0.15 0.1 
Pulse Length (mm) ~ 1.34 ~ 1.2 ~ 1 ~ 0.75 ~ 0.4 
 
 
 
An in vitro acoustic set-up was used for all acoustic studies, Fig 3.1 [Basude, 2000].  
The transducers were inserted in a deionized water bath (25°C or 37°C, identified for 
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each experiment in Chapter 4) and focused through an acoustic window of a custom 
made sample vessel.  A pulser/ receiver (model 5072 PR, Panametrics, Inc., Waltham, 
MA) was used to pulse the transducers.   
 
The pulser/receiver was set with the following parameters [Basude, 2000]: 
· Pulse Repetition Frequency = 100Hz 
· Energy Level = 1 (~13 Joules) 
· Damping Level = 3 (50 Ohms parallel output electrical resistance) 
· Gain  =  40dB 
· “1-2” switch on pulse-echo mode, position 1 
 
The above energy and damping level resulted in a peak pressure of 816 kPa at the 
focus of the 5MHz transducer, [Basude, 2000].   
The received signals were amplified to 40 dB and fed to the digital oscilloscope 
(Lecroy 9350A, Lecroy, Chestnut Ridge, NY).  The 2.0ms time-gated rms (root mean 
square) data was collected and analyzed using Labview (National Instruments, Austin, 
TX, USA).  
Two sample vessels were used for the in vitro acoustic experimentations, one for the 
degradation, dose and time response studies and one for the attenuation experiments.   
The in vitro degradation, dose and time response vessel was made of two 50 ml 
plastic centrifuge tubes (diameter = 30mm, length = 115mm, VWR Scientific, West 
Chester, PA, USA), one with the end cut off, and attached one on top of the other (cut 
end to open end) to allow a total volume of 100 ml, and the ability to securely close with 
  
46 
a screw cap.  The in vitro attenuation sample vessel used was a custom made open 
rectangular container (width = 50mm, length = 100mm, and height = 178mm) with a total 
capacity greater than 1000mL.  The water tank was equipped with a stable mounting for 
both sample vessels.  The transducers were positioned relative to each of the vessels such 
that the pressures within the container were constant and mimicked in vivo pressures 
(7mmHg) [Basude, 2000].   
An average of 50rms measurements were taken of phosphate buffered saline (PBS) 
without agent (mVbaseline).  The average of 50rms measurements were also taken of PBS 
with agent (mVagent).  A ten second delay was allotted after suspension of the agent in 
PBS to ensure proper mixing (prior to taking the measurements).  
The backscatter acoustic enhancement of the agent was calculated in reference to the 
baseline signal, equation 3.2, [Basude 2000; Forsberg et al., 1997] 
 
 Backscatter Enhancement  (dB) = 20*Log (mVbaseline / mVagent)  (3.2)  
 
3.3.1.1 In Vitro Dose Response 
Dose response curves were constructed to test the echogenicity of the microcapsules 
prepared by each method.  This was done by either a rapid or standard protocol, 
depending on the potential of the capsule preparation method to yield highly echogenic 
capsules suitable for further study.   
A rapid, cumulative dose response, method did not take into account the gradual 
destruction of the capsules, and thus loss of the signal over time.  However, it was used to 
in order reach an optimized contrast agent with minimal time and material loss.  The 
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custom-made vessel was filled with 50 ml of PBS.  The first dose (defined below) was 
added to the PBS in the vessel, and the acoustic enhancement was measured.  Every dose 
thereafter was added in a cumulative fashion to the same 50ml of PBS.   
In the standard, more time consuming, protocol the dose was placed in the custom-
vessel with 50ml of PBS and the acoustic enhancement was measured immediately.  The 
PBS with the suspended agent was discarded, and the procedure was repeated for each 
increased dose. 
All dose response curve values are based on an average of three readings each from 
three different sample preparations (n=9).  
In vitro dose:  For the purpose of the in vitro research presented here, a dose is 
defined as the weighed amount of microcapsules per volume of buffer in which they are 
suspended. For each type, Native, Phase I and Phase II agents, the dose level varies and is 
dependent on their acoustic enhancement properties.  To minimize errors of weighing out 
small amounts of microcapsules needed for each dose, a bulk lot was prepared.  The total 
amount of microcapsules that were needed for the total dose response curve were 
weighed and placed into a 20mL glass vial.  Microcapsules were then suspended in PBS, 
which was added to the vial.  The appropriate volume was pulled from the vial and added 
to 50mL of PBS in the sample vessel to give the required dose.     
 
3.3.1.2 In Vitro Time Response 
Time response curves were constructed to test the destruction of the capsules and loss 
of signal over time.  The microcapsule dose was placed in the sample vessel, the acoustic 
enhancement was measured after a 10 second delay from the time the microcapsules were 
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first placed in PBS, time was recorded as zero minutes, and acoustic enhancement was 
measured every five minutes thereafter for 20 minutes. 
All time response curve values are based on an average of three readings each from 
three different sample preparations (n=9) 
 
3.3.1.3 In Vitro Attenuation Testing 
Attenuation vs. frequency was calculated, by a method similar to that described by de 
Jong et al, over the –6dB bandwidth of five transducers listed in Section 3.3.1.  
Experiments were carried out in an open sample container with a magnetic stirrer.  
The sample container was filled with 650ml of PBS.  An air-backed reflector was placed 
in the rectangular container.  The broadband transducer was focused on the reflector and 
driven with a single pulse (in pulse echo-mode).  The received signal was fed to the 
oscilloscope and an average of 50 FFTs (fast fourier transforms) of the reflected 5ms 
range-gated (250 segments) was calculated.   A microcapsule stock solution was 
prepared, by weighing the microcapsules (0.06g) into a vial and adding in 1mL of 
phosphate buffered saline solution (PBS) pH 7.4 (25°C).  A 300mL aliquot from the stock 
solution was injected into the sample container and an average of 50 FFTs were 
calculated with the method described above (a dose response curve indicated that this 
dose gave ~23 dB enhancement).  The difference of the base FFT (PBS) and the FFT of 
the attenuated signal (PBS plus agent) was presented as attenuation (dB/cm) (where 
distance is 0.6cm) verses frequency.  The experiment was repeated with each of the five 
transducers.   
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3.3.2 In Vivo Acoustic Testing 
In vivo tests on New Zealand white rabbits were carried out at Thomas Jefferson 
University Hospital, Philadelphia, PA, USA).  The rabbits were within the weight range 
of 2.0-5.0 Kg. The rabbits were sedated with an intramuscular injection of 0.65mg/ml of 
Ketamine hydrochloride (KetasetÒ, Aveco) and xylazine hydrochloride (GemimiÒ).  
Anesthetic gas maintained the effect.  After each experiment the rabbit was sacrificed by 
a lethal dose of pentobarbital (Beuthanasia).   
The contrast agent was weighed and suspended in saline prior to injection.  The agent 
was injected through a catheterized ear vein with an 18-gauge needle.  Immediately after 
injection, the injection port was flushed with 5cc of saline.  Power Doppler imaging of 
the kidney was performed using an abdominal scan (Appendix D).   
 
3.3.2.1 In Vivo Dose Response 
In vivo dose response studies were carried out on four different rabbits.  Three dose 
response curves were constructed (n=3 per curve).  A custom made silex 10 MHz cuff 
transducer was placed around the surgically exposed distal aorta below the renal arteries.  
This setup reduces interference from intervening tissue and noise from respiratory 
movements.  A pulsed Doppler instrument (SDD 600; Vingmed Sound, Oslo, Norway) 
recorded the quadrature audio outputs.  The contrast enhancement (in dB) was calculated 
(the change in power over time) from the recorded data. 
In vivo dose:  For the purpose of in vivo research presented in this thesis, dose is 
defined as the volume of saline (with known amount of microcapsules) per kilogram of 
animal weight.  A vial containing 0.04g of dried agent was prepared for in vivo 
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experimentation.  The vial contents were suspended in 1mL of saline prior to the start of 
the experiment.   
 
3.3.2.2 In Vivo Time Duration 
Time response was manually calculated from the time of initial visualization of 
contrast from the agent to the end of the contrast effect as judged by a trained 
sonographer at Thomas Jefferson University Hospital.   
 
3.4 CROSS SECTION OF THE POLYMER CONTRAST AGENT  
The internal structure of the contrast agent was examined.  The three methods used in 
the attempt to cross-section the contrast agent are described and presented below.  
 
3.4.1 Embedding in Epoxy and Cross Sectioning 
To cross-section the contrast agent with a silicone carbide wheel they must first be 
embedded in epoxy.  A custom-made Teflon mold was made to include cylindrical 
pockets, which were open on both sides (top and bottom).  The bottom end was blocked 
with a Teflon cylindrical plug.   
The dried contrast agent was suspended in wet epoxy (Teflon was used to prevent 
adhesion), by manual mixing with a wooden spatula on a foil surface. The suspended 
mixture was placed in the pockets of the mold.  The wet epoxy mixture was allowed to 
dry for 24 hours.  The blocking plug was carefully pushed upwards releasing the dried 
mixture from the mold.  The dried epoxy mixture was placed in a 20mL glass vial, which 
was covered with parafilm and stored in a 4°C refrigerator until needed.  
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The dried cylindrical epoxy mixture was placed in a holder of a Struers Accutom-5 
(Struers, Westlake, Ohio) and sliced with a silicone carbide wheel.   
 
3.4.2 Embedding in Epoxy and Polishing 
To obtain a cross section of the contrast agent by a polishing method, the dried 
contrast agent was placed in the bottom of a thin-walled Teflon container and wet epoxy 
was poured on top and left to dry for a total of 24 hours.  The thin-walled Teflon was cut 
and peeled off from around the dried epoxy.  The bottom side of the dried epoxy (the side 
with the agent) was polished on a Struers Roto-POL 22 machine with multidose colloidal 
silica (Struers, Westlake, Ohio).  The polished surface was washed 5 times with 
deionized water to remove the polished debris.  
 
3.4.3 Probe Sonication 
Dried contrast agent was suspended in 10mL of deionized water and probe sonicated (XL 2020 
ultrasonic processor, Misonix, Inc., Farmingdale, NY) at 110 watts and 20kHz for 5 minutes.  
The sonicated suspension was freeze dried for 4 days for full dehydration of the contrast agent.    
 
3.5 MICROSCOPY 
The surface and cross section morphology of the microcapsules were examined by 
use of a scanning electron microscope (SEM) (Amaray (model 1830D), Bedford, MA).  
The samples were gold coated under reduced pressure with a sputter coater for 200 
seconds prior to examination. 
 
 
  
52 
3.6 CAPSULE DEGRADATION SET-UP 
Two experimental groups consisting of three different samples each (where n=3 per 
sample) were prepared for the degradation study. The first group used Phase I contrast 
agent (agent prepared with camphor), within this group the three samples were named 
Phase I-C, Phase I-5 and Phase I-10 (designations C, 5 and 10 indicate control, 5 MHz 
and 10 MHz).  The second group employed Phase II contrast agent (agent prepared with 
both camphor and ammonium carbonate), within this group the three samples were 
named, Phase II-C, Phase II-5 and Phase II-10 (designations C, 5 and 10 indicate control, 
5 MHz and 10 MHz). The contrast agent (0.34g) was weighed in 50ml glass containers, 
suspended in (40ml) PBS, pH 7.4, and stored tightly capped in an incubator at 37°C on a 
shaker for the duration of the experiment.   
A 1mL aliquot was taken from each sample immediately upon suspension of the 
agent in PBS (0 hours).  Representative samples were assured by use of a magnetic stirrer 
during sampling.  The aliquots were filtered through a 0.2mm syringe filter to remove the 
agent, which was then discarded; the filtrate was then analyzed with the use of HPLC 
(high pressure liquid chromatography).   
Samples Phase I-C and Phase-II-C were the controls and were not exposed to 
ultrasound at any point during the experiment.  Samples Phase I-5 and Phase II-5 were 
exposed to 15 min of insonation in the sample vessel (Section 3.2.3.1) at 5MHz, and 
samples Phase I-10 and Phase II-10 were exposed to 15 min of insonation in the sample 
vessel at 10MHz, immediately after the first aliquot (0 hours) was taken.  All acoustic 
experiments were carried out in the in vitro acoustic tank (Fig. 3.4) with continuous 
stirring using a magnetic stir bar.  After the first 15 minutes, a second aliquot (1mL) was 
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taken from each sample (handled as previously described).  Immediately thereafter, all 
samples were placed in the incubator.     
Aliquots (1mL) were collected from the samples in the incubator at specified time intervals, 
24, 72 and 168 hours, and prepared for HPLC analysis.   
 
3.7 HPLC (HIGH PRESSURE LIQUID CHROMOTOGRAPHY) ANALYSIS  
HPLC is a process to obtain information about a sample.  This includes identification, 
quantification and resolution of the sample.   
The buffer (from the filtered aliquots) collected at specified time intervals was analyzed on an 
HPLC (Waters 2690 Separations Module) using an Inertsil ODS-3V, 100A°, 5mm, 250 x 4.6 mm 
column (Alltech, Deerfield, IL).  The mobile phase for the separation of the two acids was 0.1M 
ammonium dihydrogen phosphate, pH 2.5, with a flow rate of 1.0ml/min.  The detector UV was 
set for 210nm.  Three injections of 20uL each per aliquot were analyzed. 
 
3.8 PARTICLE SIZE DISTRIBUTION ANALYSIS 
A Horiba LA-910 particle size analyzer (Horiba Instruments, Irvine, CA) based on static light 
scattering methods was used to measure the size distribution of the microcapsules.   
Deionized water was used as a blank in the Horiba sample well.   Microcapsules were 
suspended in the deionized water.  Sufficient amount of microcapsules added was indicated by the 
Horiba LA-910 software.  The size distribution of the microcapsules was then taken.   
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Figure 3.1: Acoustic testing set-up.  The transducer (2.25, 5, 7.5, 10 or 15MHz) was 
inserted in a deionized water bath and focused through an acoustic window of 
a 100 ml custom made vessel.  A pulser/ receiver was used to pulse the 
transducers at a pulse repetition frequency of 100Hz.  The received signals 
were amplified to 40 dB and fed to the digital oscilloscope, which is 
connected to a computer with LabView applications [Basude, 2000].   
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 4.  RESULTS AND DISCUSSION  
(CONTRAST AGENT FABRICATION AND ANALYSIS) 
 
 
 
Results and discussion presented in this chapter pertain to the development and 
characterization of a novel polymer ultrasound contrast agent.  All results and discussions 
related to drug delivery, targeting and fabrication of nano capsules are presented in 
chapter 5.   
 
4.1 A NOVEL METHOD FOR SYNTHESIS OF A POLYMERIC CONTRAST AGENT  
The project objective as outlined in chapter 1 was to develop a novel method to 
fabricate a polymer contrast agent.  The contrast agent must meet certain physical 
characteristics (section 1.1 A1-4) as well as enhance the diagnostic image in the medical 
frequency range.   
Subsection 4.1.1 describes a previous method developed in our lab to fabricate hollow 
PLGA microcapsules.  Analysis of the developed agent and method of fabrication has 
been carried out for further characterization.   
Subsections 4.1.2, 4.1.3, and 4.1.4, present research that has led to the development of 
a novel method for the fabrication of hollow polymeric contrast agents. Subsection 4.5.5 
presents additional work that has led to further optimization of the agent.   
 
4.1.1 Encapsulation of Solid Ammonium Carbonate Particles 
Previous work in our lab has been performed to develop a method to fabricate PLGA 
contrast agents by encapsulating solid ammonium carbonate particles and later removing 
the particles by sublimation and leaving a void in their place [Narayan, March 1999].  
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The goal was to produce a contrast agent with an average diameter of less than 10mm.  
For achieving that size limitation, the grinding of the solid ammonium carbonate core 
material was essential.  A model M18/5 Vibro-energy grinding mill (SWECO, Inc., 
Florence, KY) was used for the grinding process.  Wet grinding in a solvent (one that 
does not solubilize the particles) with zirconia cylindrical pellets was established to be 
the best method for the size reduction of the core material.  Evaporation of the solvent 
under the hood for 24 hours dried the ammonium carbonate particles.  Grinding with 
petroleum ether and 1/4" zirconia cylindrical pellets, for a total of 4-5 hours yielded 
optimal results, with the production of 5.5 µm ammonium carbonate particles.  Three 
methods of microcapsule fabrication, coacervation, solvent extraction and spray drying, 
were modified to encapsulate the ground ammonium carbonate, for the production of 
ultrasound contrast agents.  In vitro acoustic enhancements for three size fractioned 
samples, 5-8, 8-10 and 20-41mm were reported for both solvent evaporation (maximum 
enhancements of 1.9dB, 2.5dB and 5.2dB respectively) and coacervation (maximum 
enhancements of 6.8dB, 8.9dB and 15dB respectively) microcapsules.  Enhancements 
reported with all spray dried microcapsules were less than 8.6dB.  In vivo testing in New 
Zealand white rabbits were carried out with these agents, (specific dB values were not 
published).       
 
4.1.1.1 Challenges Presented by Encapsulating Solid Ammonium Carbonate Particles  
Further in vitro analysis of the spray dried and solvent extraction capsules was 
required.  For this analysis spray dried and solvent evaporation microcapsules were 
provided by Dr. P. Narayan [Narayan, March 1999].  The microcapsules were prepared 
  
57 
by encapsulating and later subliming solid ammonium carbonate particles.  All 
microcapsules were fabricated with the RG 504H 50:50 PLGA polymer.   
Studies to characterize the surface morphology (Fig. 4.1, and Fig. 4.2) and size 
distribution (Fig. 4.3, and Fig. 4.4) of the provided spray dried and solvent extraction 
capsules, respectively, were carried out.  Surface morphology of both the spray dried and 
solvent extraction microcapsules indicated that most of the capsules were spherical; 
however irregularly shaped capsules (almost spherical) were also present.  The average 
mean diameter of the spray dried capsules was 9.5mm with a wide distribution from 
1.7mm to 45mm.  Similar results were seen with the solvent extraction capsules, with a 
mean diameter of 10.3mm and a distribution range from 1.7mm to 50mm.   
Acoustic enhancement experiments were carried out with these microcapsules.  
Results indicated no backscatter enhancement, with values similar to baseline (2.8dB).  
The results of these studies presented some challenges, including presence of large 
(greater than 8mm) microcapsules, aggregation of microcapsules upon suspension in an 
aqueous medium, and no acoustic enhancement properties.  These challenges are 
discussed in more detail below.  
The size distribution analysis showed presence of microcapsules with a diameter 
larger than 8mm.  In comparison, a red blood cell is a flattened biconcave disc that is 
7.5mm in diameter and 2.5mm thick, its size, shape, and flexibility allow it to travel 
unimpeded through the circulatory system [Graaff, 1995].  The hard spherical PLGA 
microcapsules do not have such advantages, making their size a crucial factor for 
unimpeded circulation after intravenous injection.  PLGA agents larger than 8mm may 
cause an embolism when injected.  Size fractionation has been used in the past to address 
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this issue [Narayan, March 1999].  The microcapsule suspension was filtered through an 
8 or 10mm nylon (Spectra) mesh to obtain a sample of microcapsules with a diameter less 
than 10mm.  Size fractionation should be a last resort, as it has many disadvantages 
including, loss of yield, and a longer (at least 24 hours) and more complex fabrication 
process.  These would lead to increased cost (polymer lost and manufacturing time) for 
the process. 
Size analysis and acoustic enhancement studies required the suspension of the 
microcapsules in a buffer solution.  Aggregation of the microcapsules occurred upon 
suspension in the aqueous solution, making it difficult to handle.  Suspension of the 
microcapsules in an aqueous solution will be required for in vivo experimentation and 
application.  Probe sonication of the microcapsules in deionized water, containing 0.01% 
Tween 80, was a method that had been investigated to disperse the agglomerates 
[Narayan, March 1999].  This method may work for the dispersion of solid 
microcapsules; however probe sonication of hollow microcapsules could result in their 
destruction (depending on parameters used) (Section 4.2.3).  Additionally not adding a 
wash step to remove excess Tween will result in the injection of suspended Tween 
particles along with the microcapsules.  
Encapsulating and later subliming solid ammonium carbonate particles in PLGA 
microcapsules should lead to the production of hollow microcapsules with backscatter 
enhancement properties.  If we keep in mind that the ammonium carbonate particles (as 
reported [Narayan, March 1999]) have a mean diameter of 5.5mm, the situation can be 
further analyzed. Microcapsules with an average diameter smaller than 5.5mm (this 
diameter does not take into account the thickness of the microcapsule polymer shell) 
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should then theoretically be solid.  Microcapsules larger than 5.5mm should, however, be 
hollow and result in acoustic enhancements greater than baseline if, in fact, they are 
encapsulating the ammonium carbonate particles and the particles are fully sublimed 
when lyophilized.  Results show this is not the case, with backscatter similar to baseline 
(2.8dB).  This led to two possible conclusions. Either the ammonium carbonate particles 
were not being encapsulated, resulting in solid polymer microcapsules or the ammonium 
carbonate particles were in fact encapsulated but they are not being fully sublimed, 
resulting in polymer capsules with an ammonium carbonate core.   
 
4.1.1.2 Testing to Determine Encapsulation and Sublimation of Ammonium Carbonate 
The microcapsules were placed in a solvent (methylene chloride), in which PLGA is 
fully soluble but ammonium carbonate is not.  If the microcapsules fully dissolve in the 
solvent it would indicate that they are composed of only PLGA, and that the ammonium 
carbonate particles were not encapsulated during the fabrication process.  If the 
microcapsules do not fully dissolve, then they are composed not only of PLGA but also 
of ammonium carbonate particles/residues, indicating that the solid particles were 
encapsulated but were not sublimed.   
Experiments were carried out with spray dried (prepared and provided by P. Narayan 
[March 1999]), solvent extraction and coacervation microcapsules (prepared by methods 
described in Sections 3.2.4 and 3.2.5, respectively).  Microcapsules were weighed 
(0.02g), placed in 20 mL of methylene chloride, covered with parafilm to prevent solvent 
evaporation and stirred for 24 hours.  The time allotted to dissolving the microcapsules 
was determined to be sufficient by consideration of the time required to dissolve 
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unprocessed PLGA in methylene chloride, ~5minutes.  All experiments resulted in a 
murky solvent with suspended brownish like sticky particles.  It was concluded that the 
ammonium carbonate was encapsulated by the method proposed but was not sublimed.   
 
4.1.1.3 Testing to Determine Solvent Effects on Ammonium Carbonate 
Ammonium carbonate was ground in petroleum ether by the method described in 
Section 4.1.1 [Narayan, March 1999].  The dried ammonium carbonate particles were 
placed in the freeze dryer (n=3) with three samples of unprocessed ammonium carbonate 
(as the control).  The experimental samples did not sublime and left a sticky residue 
behind; control samples completely sublimed.  It was concluded that petroleum ether was 
not an optimal solvent for grinding ammonium carbonate.  Tests were repeated with 
hexane, which resulted in a similar residue, and was ruled out as an alternate solvent.    
Getting the size of solid ammonium carbonate particles small enough (<5mm) without 
altering the properties of the ammonium carbonate such that it remains a sublimable 
substance was the main challenge of the method proposed.  An alternate method of 
producing hollow PLGA microcapsules by encapsulation of a dissolved sublimable core 
was hypothesized to meet the requirements of the ultrasound contrast agent as outlined in 
the objectives section of this thesis (Chapter 1).  Encapsulation of a dissolved core 
material eliminates problems associated with size reduction.  
 
4.1.2 Fabrication of Native Agent by a W/O/W Double Emulsion Process 
The double emulsion method was selected as the capsule fabrication method to be 
investigated for the development of PLGA contrast agents via encapsulation and 
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sublimation of dissolved substances.  The ability to encapsulate both hydrophilic and 
hydrophobic substances through the double emulsion method made it an appealing 
selection.   
The double emulsion technique had been used in the past to fabricate hollow and 
porous microcapsules.  The microcapsules fabricated had diameters that ranged from 
30mm to 300mm [Crotts et al., 1995].  Additionally the double emulsion technique had 
been used to prepare drug loaded, 1 and 5 mm, PLGA microcapsules [Igartua et al., 
1998].  The experimental parameters presented in both methods were investigated and 
adapted to fabricate 1mm hollow microcapsules. 
The adapted double emulsion method was used to fabricate Native agent and to 
establish a base line to which all future experiments could be compared.  Polymers 
(RG504H and DL 3A), from two different vendors (Boehringer Ingelheim Chemicals and 
Alkermes, respectively) were investigated to identify the polymer that fabricates Native 
agent with the desired criteria.  Ideally the agent should be spherical and have a uniform 
size distribution with a maximum diameter of 8 mm.  Additionally, the agent should not 
aggregate when suspended in an aqueous medium.   
 
4.1.2.1 Properties of the Selected Polymers  
Properties of two polymers chosen for Native agent fabrication were compared and 
summarized in Table 4.1: 
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Table 4.1: Polymers used in the preparation of Native Agent  
 
 
Polymer Co-
polymer 
Ratio 
Inherent 
Viscosity 
(I.V.) 
Polydispersity 
(PDI) 
Molecular 
Weight 
(M.W.) 
End 
Group 
RG504H 50:50 0.49 dl/g 3.22 44 Kd Acid 
DL 3A 50:50 0.38 dl/g 1.8 47 Kd Acid 
 
 
Copolymer Ratio 
The copolymer ratio with respect to PLGA, is the ratio of lactic acid to glycolic acid.  
The copolymer ratio of the selected polymers was 50:50.  This ratio was chosen for two 
main reasons 
· It was the polymer used in the fabrication of polymer contrast agents via 
encapsulation of solid ammonium carbonate particles [Narayan, March 1999].  
Maintaining the co-polymer ratio allows direct comparison of results. 
· The long term objective, a targeted imaging and drug delivery system, (Section 
1.1), requires the contrast agent to be anchored to a specific site.  Ideally the agent 
should be eliminated from the body once it has served its required purposes.  PLGA 
50:50, has a relatively short degradation time (weeks-months) which is compatible 
with the therapeutic need.   
 
Molecular Weight (MW) 
The polymers had similar MW’s of 44Kd and 47Kd for RG504H and DL 3A, 
respectively.   
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End Groups 
Both polymers studied had acid end groups.  The acid end groups make the polymer more 
hydrophilic and increase its ability to uptake water and thus increase degradation time.  
While this was not a crucial factor in capsule preparation, its presence in both polymers 
was important for consistency of the results.   
 
Inherent Viscosity (I.V.) 
The I.V. is a measure of molecular weight. The I.V. of the RG 504 H polymer, 0.49dl/g 
was slightly higher then that of the DL 3A polymer, 0.38dl/g.  This small difference is 
not expected to have an effect on the results.  
 
Polydispersity (PDI) 
The PDI is a measure of the molecular weight distribution of the polymer.  The PDI of 
the RG 504 H polymer, 3.22 was greater then the PDI of the DL 3A polymer, 1.8.  This 
difference may have an effect on the results.  
 
4.1.2.2 Properties of the Selected Surfactant 
Polyvinyl alcohol (PVA) was the surfactant investigated for use in the development 
of Native agent.  PVA is produced by polymerization of vinyl acetate, which is then 
hydrolyzed to poly vinyl alcohol.  Three different MW (133,000, 25,000 and 6,000) 
PVA’s were purchased and investigated, each hydrolyzed at a different percent (99, 88 
and 80, respectively), as shown in Table 4.2.   
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Table 4.2: Surfactants used in the preparation of Native agent 
 
 
PVA MW PVA % Hydrolysis 
133,000 99 
25,000 88 
6,000 80 
 
 
Percent hydrolysis refers to the amount of poly vinyl acetate that is hydrolyzed and 
hence the number of hydroxyl groups present on the surfactant.  Higher percent 
hydrolysis of PVA generally yields a stronger surfactant.  Additionally a higher 
molecular weight results in a more viscous solution and increased surfactant strength.   
Thus PVA with three different surfactant strengths were tested in the fabrication of 
Native agent.  PVA with MW 133,000 had the strongest surfactant strength and PVA 
with MW 6,000 had the weakest.  
 
4.1.2.3 Polymer and Surfactant Combinations Used to Fabricate Native Agent 
Different polymer and surfactant combinations were used in the fabrication process of 
Native agent, Table 4.3, to determine which combination fabricated spherical, uniform 
microcapsules with a smooth surface.  
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Table 4.3: Polymer and PVA combinations used in the  
preparation of Native Agent 
 
 
 
                  
 
 
 
 
   
 
 
 
Microcapsules, RG133, RG25 and RG6, were prepared with the RG 504 H polymer 
and with three different surfactants of PVA MW 133,000, 25,000 and 6,000, respectively.   
Fabrication of sample RG133 resulted in spherical microcapsules that were attached 
to a sponge-like matrix assumed to be PVA, Fig. 4.5 (the presence of the microcapsules 
was only detected after visualization under the SEM).  Separation of the capsules from 
the sponge-like matrix was difficult and not pursued.  Analysis of microcapsule 
aggregation tendencies was thus not possible.  
Fabrication of sample RG25 resulted in the production of spherical, uniform capsules 
with a smooth surface, Fig. 4.6.  The microcapsule yield was 85-90% and capsules were 
easily suspended in an aqueous solution.    
Fabrication of sample RG6, Fig. 4.7, unexpectedly resulted in the production of 
spherical microcapsules with large visible dents seen throughout the microcapsule 
preparation.  The microcapsule yield was also 85-90% and capsules easily suspended in 
an aqueous solution.   
Sample Name Polymer PVA MW 
RG133 RG 504H 133,000 
RG25 RG 504H 25,000 
RG6 RG 504H 6,000 
DL25 DL 3A 25,000 
DL6 DL 3A 6,000 
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SEM analysis led to the observation that microcapsules RG25 and RG6 did not 
survive (melted) the duration of image capture at a magnification greater than 6000X, 
whereas the RG133 microcapsules were stable for image capture at magnification levels 
greater than 17,000X. 
Microcapsules, DL25 and DL6, were prepared with the DL 3A polymer and with two 
different surfactants of PVA MW 25,000 and 6,000, respectively, Table 4.3.  Because of 
the difficulties experienced in separating the capsules of sample RG133 from the sponge-
like matrix, the 133,000 MW PVA was not investigated for fabrication of microcapsules 
with the DL 3A polymer.   
Fabrication of sample DL25, Fig. 4.8, resulted in the production of uniform, spherical 
capsules that were directly comparable to sample RG25, Fig. 4.6. The microcapsule yield 
was also 85-90% and capsules easily suspended in an aqueous solution.   
Fabrication of sample DL6, Fig 4.9, resulted in the production of uniform, spherical 
capsules with a smooth surface; these were very different from sample RG6, Fig. 4.7, 
which had visible dents in the surface morphology.  Both preparations gave a capsule 
yield of 85-90% and capsules easily suspended in an aqueous solution.   
The results obtained from the various polymer/surfactant combinations for 
development of Native agent have been summarized, Table 4.4.  
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 Table 4.4: Summary of microcapsules developed  
in the process of Native agent fabrication   
 
 
 
 
 
 
 
The RG 504 H polymer produced microcapsules with visible variations in their 
surface morphology.  Microcapsules adhered to a sponge-like matrix were produced 
when fabricated with PVA MW 133,000, Fig. 4.5.  Dented microcapsules were produced 
when fabricated with the 6,000 MW PVA, Fig 4.7.  Thus all further work to develop an 
optimized contrast agent was pursued with the DL 3A polymer, which consistently 
produced spherical capsules with a smooth surface, Fig. 4.8 and 4.9.  DL 3A is also a 
more cost effective polymer than RG 504 H.   
 
4.1.2.4 Acoustic Testing of Two Possible Native Agents 
The two possible Native agents as determined from Section 4.1.2.3, were samples 
DL25 and DL6, Fig 4.8 and 4.9 respectively.  Both these samples were tested for their 
echogenic properties using the in vitro acoustic set-up, Fig. 3.1.  Initially, it was assumed 
Sample 
Name 
Yield Surface Morphology Suspension in 
Aqueous Solution 
RG133 N/A Spherical with smooth 
surface. Capsules adhered 
to a sponge-like matrix 
N/A 
RG25 85-90 % Spherical with smooth 
surface 
Easily 
RG6 85-90 % Spherical with “dented” 
surface 
Easily 
DL25 85-90 % Spherical with smooth 
surface 
Easily 
DL6 85-90 % Spherical with smooth 
surface 
Easily 
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that the sublimable agent (water) was not encapsulated in any significant quantity through 
this process and enhancement was not expected. 
A cumulative dose response curve was constructed to test the echogenicity of the 
capsules at 5 MHz, Fig. 4.10.  Doses ranged from 0.02mg/ml to 0.06mg/ml.  Experiments 
were run three times for both samples, DL6 and DL25. 
Unexpectedly however backscatter enhancement was seen.  Results (Fig. 4.10) 
showed that at the highest dose chosen (0.6 mg/ml) the DL25 capsules gave an average 
acoustic enhancement of 9.1 dB (±0.14) whereas the DL6 capsules gave an enhancement 
of 15.6 dB (± 1.76).  Differences in the dose response curves were found to be 
statistically significant (p<0.01). 
The fabrication process chosen to develop Native agent could explain this 
enhancement.  The double emulsion process is a water in oil in water (W/O/W) process, 
Appendix B, Fig. B.1.  The first water in oil (W/O) emulsion is formed by probe 
sonication of a polymer/methylene chloride solution with deionized water, this results in 
the dispersion of water droplets within the oil phase.  The second emulsion (W/O/W) is 
formed by homogenization of the first W/O emulsion in a PVA solution.  This causes the 
oil phase with the dispersed water droplets to form into microcapsules, Fig. 4.11.   Freeze 
drying the formed microcapsules results in the sublimation of the encapsulated water 
droplets and the formation of dried PLGA microcapsules with voids in their place.  These 
voids give Native agent its enhancement properties.    
The surface morphology of samples DL25 and DL6 (Fig. 4.8 and 4.9, respectively) 
may have suggested that the two are similar;  however, the 6.5 dB difference between the 
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two samples indicated that the samples are morphologically dissimilar, most likely in 
their internal structure.   
Following from the explanation of the fabrication process, it is hypothesized that the 
DL6 agent may have encapsulated more water droplets than the DL25 agent. This would 
give the DL6 agent a more porous interior and result in a higher acoustic enhancement.  
Scanning electron micrographs indicated that these agents are less than 8mm (Fig. 4.8 
and 4.9.).  Size analysis was performed on DL25 Native agent, Fig. 4.12, which showed a 
size distribution with a mean diameter of 1.2 mm, and a size distribution range from 0.5 
mm to 6 mm.   
The enhancement results, 15.6 dB and 9.1 dB, for Native agent (DL6) and Native 
agent (DL25), respectively, (for doses of 0.6mg/ml) were compared to the enhancements 
(1.9dB and 6.8dB) reported from the 5-8mm solvent evaporation and coacervation 
microcapsules, respectively (Section 4.1.1).  It was concluded from these results that 
Native agent fabricated by the double emulsion method, which encapsulated and 
sublimed small droplets of water, gave higher acoustic enhancements than the 
microcapsules produced by encapsulation of solid ammonium carbonate particles by the 
solvent evaporation or coacervation techniques.    
While Native agent (DL25) and Native agent (DL6) gave promising results, the 
acoustic enhancements obtained did not fulfill the backscatter enhancement requirements 
(~20dB) outlined in Chapter 1 of this thesis.   
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4.1.3 Fabrication of Phase I and Phase II PLGA Contrast Agents  
Novel fabrication methods were researched to develop PLGA contrast agents with 
acoustic enhancements up to 20dB.  The double emulsion process used to fabricate 
Native agent was modified to encapsulate dissolved core materials and later sublime 
those materials from the microcapsules.  
 
4.1.3.1 Fabrication of Phase I Contrast Agent  
A novel method of developing Phase I contrast agent was investigated to increase the 
acoustic enhancement properties of Native agent.  Phase I agent was developed by 
encapsulating a substance that is dissolved in the oil phase and later subliming that 
substance from formed microcapsules.  Camphor, a hydrophobic substance that is easily 
removed by sublimation, was chosen as the material to be encapsulated.   
Phase I agents were fabricated by encapsulating and later subliming camphor by a 
modified double emulsion method (Section 3.2.2).  This method still encapsulated the 
water droplets but additionally encapsulated dissolved camphor.  The camphor was 
dissolved in the oil phase and then deionized water was suspended in this same phase.  
The first water in oil emulsion caused dispersion of the water droplets in the oil phase 
(which now contained dissolved camphor).  The second emulsion caused the oil phase 
(with the dissolved camphor and the dispersed water droplets) to form into 
microcapsules.  Freeze drying the formed microcapsules resulted in the sublimation of 
the encapsulated water and camphor and the formation of dried microcapsules with voids 
in their place, Fig 4.13.  It was predicted that the acoustic enhancement of both Native 
agents, DL25 and DL6, would be increased by this modification.   
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4.1.3.1.1 Optimal Amount of Camphor for Encapsulation (Comparison to DL25 Native 
Agent) 
An optimization study that encapsulated different amounts of camphor, 0.025g, 
0.05g, 0.1g, and 2.5g, was initially carried out under the same conditions as the DL25 
agent (with the exception of added camphor).  Microcapsules fabricated by encapsulation 
of 0.025g, 0.05g, 0.1g, and 2.5g were name DL25C-0.025, DL25C-0.05, DL25C-0.1, and 
DL25C-2.5, respectively, collectively they were referred to as the DL25C.  This study 
was then to be repeated under the same conditions as the DL6 agent (with the exception 
of added camphor).   
In vitro acoustic analyses were carried out with the DL25C microcapsule series, with 
doses in the range of 0.02mg/ml to 0.6mg/ml.  Cumulative dose response studies of the 
DL25C microcapsule series (with camphor) were compared to the cumulative dose 
response curve of Native agent DL25 (without camphor), Fig. 4.14.  Experiments were 
run three times for each sample (except DL25C-2.5, which gave poor results), average 
enhancement (dB) values were plotted with ± error bars indicating standard error from 
the mean. 
Sample DL25C-2.5 (microcapsules prepared with 2.5g of camphor), had a strong 
smell of camphor, and it was assumed that lyophilization for 24 hours was not sufficient 
to remove all the encapsulated camphor.  These capsules gave an acoustic enhancement 
of 9.1 dB at a 0.6mg/ml dose, similar to that of Native agent DL25, prepared without 
camphor (9.1dB at a dose of 0.6mg/ml).   
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Sample DL25C-0.1 (microcapsules prepared with 0.1g of camphor) gave an acoustic 
enhancement of 15.3 dB (±1.35) at the 0.6mg/ml dose.  These capsules had a slight smell 
of camphor, indicating that not all the camphor was removed.   
Sample DL25C-0.05 (microcapsules prepared with 0.05g of camphor) gave an 
acoustic enhancement of 19.3 dB (± 2.8) with the 0.6mg/ml dose.  These capsules did not 
smell of camphor, and it was assumed that the high acoustic response was due to the 
removal of the encapsulated camphor.   
Sample DL25C-0.025 (microcapsules prepared with 0.025g of camphor) did not 
smell of camphor and gave an acoustic enhancement of 17.9 dB (±0.84), with the 
0.6mg/ml dose.   
Differences in the dose response curves of all samples were compared and found to 
be statistically significant using a 2-way ANOVA (p < 0.01).  This method of 
encapsulating dissolved camphor did in fact complement the acoustic enhancement of 
Native agent DL25.  DL25C-0.05 showed the best results with an increase of 10.15 dB 
from Native agent DL25, for a total enhancement of 19.3 dB when encapsulating 0.05g 
of camphor.  
The amount of camphor to be encapsulated that would result in maximum acoustic 
enhancement was now determined.  All further fabrication experiments encapsulated this 
amount, 0.05g of camphor.   
 
4.1.3.1.2 Encapsulation of Camphor (Comparison to DL6 Native Agent) 
A study to increase acoustic enhancement of Native agent DL6 by encapsulation of 
camphor (DL6C) was then carried out.  The acoustic enhancement of the capsules was 
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studied; however, a cumulative dose response was difficult to construct because the 
capsules were very unstable.  It was determined that the measurable acoustic properties of 
the capsules were poor with only about a 12 dB enhancement with the 0.6 mg/ml dose.  
The enhancement given by the DL6C microcapsules was about 3.5 dB lower than Native 
agent DL6.  It was concluded that the preparation with camphor and 6,000 MW PVA 
resulted in weak microcapsules, capsules that did not have a strong enough shell to 
remain intact when suspended in PBS and exposed to ultrasound. 
 
4.1.3.1.3 Acoustic Characterization of Phase I Agents 
The capsules that have shown the greatest enhancement thus far were those prepared 
with the DL 3A polymer, 25,000 MW PVA, and encapsulated 0.05g of camphor 
(DL25C-0.05), and were named Phase I agents.  A single dose of 0.6 mg/ml was tested to 
eliminate the effect of destruction of bubbles over time.  A 23.1 dB enhancement was 
achieved as compared to the 19.3 dB obtained from the 0.6mg/ml dose, (the 6th dose of 
the cumulative dose response curve).  The difference of about 3.8 dB accounts for the 
destruction of bubbles over time, which can be seen in the time response curve 
constructed from a 0.4mg/ml dose (of the same Phase I agent), Fig. 4.15.  After 20 
minutes the acoustic enhancement of 21dB at time zero, had decreased by only 3 dB 
giving an acoustic enhancement of 18 dB.  All experiments were conducted at room 
temperature.  
 
In vitro results indicated that the method of microcapsule preparation by 
encapsulating and later removing camphor produced Phase I ultrasound contrast agents 
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that gave up to 23 dB enhancement with a 0.6mg/ml dose of capsules.  The contrast 
agents are relatively stable over time at 25° C with only minor bubble destruction (4dB 
loss) seen in 20 minutes.   
 
4.1.3.2 Fabrication of Phase II Contrast Agent  
While the method that encapsulated and sublimed dissolved camphor produced an 
agent that gave acoustic enhancements of up to 23 dB (Phase I agent), it was further 
modified in an attempt to improve the acoustic properties.  The modification was to 
encapsulate a third water sublimable substance in the water phase, to develop an 
optimized Phase II agent.  The third sublimable substance should be water-soluble in 
order to dissolve in the water phase and should be easily broken down when lyophilized.   
Ammonium carbonate met both the specified requirements, (it is water soluble in the 
aqueous phase and is easily removed by freeze drying (when it breaks down to ammonia, 
carbon dioxide and water) and so was chosen as the substance for encapsulation and for 
the fabrication of Phase II agents, Fig. 4.16.   
It was hypothesized that additionally encapsulating and later subliming the 
ammonium carbonate would create more void pockets within the microcapsule, and thus 
enhance the acoustic properties of the Phase I agent, Fig. 4.16. The fabrication process to 
develop a Phase II agent would thus encompass the encapsulation of water droplets (as 
seen initially with Native agents DL6 and DL25, and later with the Phase I agent), 
dissolved camphor in the oil phase (as seen with Phase I agent) and dissolved ammonium 
carbonate within the water phase.  The water droplets, camphor, and ammonium 
carbonate would collectively get sublimed when the microcapsules were freeze dried.   
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The ideal amount of ammonium carbonate to be encapsulated was unknown.  An 
ideal amount was defined as that amount which would give maximum acoustic 
enhancement while retaining the stability properties of the microcapsules.  Encapsulation 
of “too much” ammonium carbonate could lead to the fabrication of very thin shelled 
microcapsules that are easily susceptible to destruction, and do not remain intact for the 
duration of imaging.  
Phase II contrast agent was fabricated (Section 3.2.3) with a 4w/v% ammonium 
carbonate solution, which was chosen at random as a starting point.  No problems were 
experienced during the fabrication process.   
 
4.1.3.2.1 Physical Characterization  
Size distribution and surface morphology of the fabricated Phase II agent were 
analyzed.   
Size distribution was studied on the Horiba size analyzer, Fig. 4.17.  The size 
distribution was narrow with 99.6% of the microcapsules diameter ranging from 0.4µm 
to 4.0µm.  The microcapsules had a mean diameter of 1.21µm.  The Coulter Multisizer II 
was also used to investigate the size distribution of these microcapsules and showed that 
the distribution had a mean diameter of 1.24mm, Fig. 4.18.   
Scanning electron microscopy was used to study the surface morphology of the Phase 
II contrast agent, Fig. 4.19. The SEM shows spherical microcapsules with a smooth 
surface.   
The adapted preparation method used to fabricate Phase II agent gave a yield of 75-
85%, similar to that of the Phase I agent. 
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4.1.3.2.2 Effects of PVA Temperature  
The method of fabricating Phase II agent resulted in batch to batch acoustic 
enhancement variations, ranging from 12 dB to 20 dB for the same dose, 0.02mg/ml.  
This variation from one preparation to the next was not seen with either Native agent 
DL25 or Phase I agent.  Assessment of the experimental conditions and protocol was 
conducted.  Up until this point, the PVA solution had been taken out of the refrigerator 
(4°C) at the start of the microcapsule fabrication method and placed on the counter top at 
room temperature (26°C) until use.  It was hypothesized that the temperature of the PVA 
solution used during the capsule fabrication process may have had an effect on the 
echogenicity of Phase II agent.   
To test this hypothesis, Phase II contrast agent was prepared with three different PVA 
solution temperatures, 4°C, 26°C and 45°C; samples were referred to as DL25AC4, 
DL25AC26 and DL25AC45, respectively.  Dose response curves were constructed for 
each of the preparations, Fig. 4.20.  Experiments were run three times for each sample, 
average enhancements were plotted with ± error bars indicating standard error from the 
mean.   
The dose range of 0.02mg/ml-0.6mg/ml (that had been selected for Native agent and 
worked for the Phase I agent) resulted in shadowing.  This dose range was concluded to 
be too high for testing the Phase II agent. Phase II agent was to be tested with doses that 
ranged from 0.006 mg/mL to 0.036 mg/ml.   
With a dose of 0.03mg/ml, the capsules prepared with PVA at 45°C (DL25AC45) had 
the lowest acoustic enhancement of 8.6 dB (±3.8) in comparison to those prepared with 
PVA set at room temperature (DL25AC26), 26°C (16.2 dB, ±2.8) and (DL25AC4) at 4°C 
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(19.6 dB, ±1.2).  The ± standard errors from the mean were on average smaller with the 
cold PVA than with either the warm or room temperature PVA, as expected in a 
temperature-dependant phenomenon.    
The results were found to be statistically significant using a 2-way ANOVA (p < 
0.01), best results were obtained with the PVA solution set at 4°C, sample DL25AC4, 
and this was concluded to be the final version of Phase II agent.  It is believed the 
criticality of surfactant temperature has not been reported previously.   
 
4.1.3.2.3 In Vitro Acoustic Testing of Phase II Contrast Agents 
A non-cumulative dose response at 2.25, 5, 7.5 and 10 MHz was constructed from 
Phase II agent (prepared with cold PVA), Fig. 4.21.  The doses tested were in the range 
of 0.002 mg/ml to 0.012 mg/ml.   
Acoustic enhancements of 15.9 (±0.3), 24.5 (±0.6), 25.9 (±1.7) and 21.4 (±0.4) dB 
were seen at 2.25, 5. 7.5 and 10 MHz, respectively, with a dose of 8µg/ml.  Dose 
response curve at 2.25 MHz was found to be statistically significant (p<0.05) from dose 
response curves at 5 MHz and 7.5MHz. All other curves were not statistically different.   
In vitro time response acoustic studies show that the capsule stability at 25°C is good 
(loss of only 4 dB over 20 minutes), Fig. 4.22. 
In vitro acoustic studies indicated that the encapsulation of dissolved ammonium 
carbonate in the water phase along with dissolved camphor in the organic phase for the 
development of Phase II agent does not increase the maximum achievable acoustic 
enhancement from Phase I agent, ~25dB compared to ~23dB, respectively.  However, it 
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dramatically decreases the total dose needed to reach that value from 0.6mg/ml to 
0.004mg/ml, for Phase I and Phase II agent, respectively. 
 
4.1.4 Summary of Acoustic Enhancement Properties for Different Polymeric 
Contrast Agents 
 
This study led to the development of novel protocols for contrast agent 
fabrication.  Acoustic enhancement results of agents fabricated via different methods are 
summarized in Table 4.5.  All results presented are from cumulative dose response curves 
(maximum enhancement at the maximum dose), samples insonated at 5MHz.  
 
Table 4.5: Summary of Acoustic Enhancement from  
Contrast Agents Prepared by Different Methods 
 
 
 
 
 
 
 
 
 
 
 
· Encapsulation of solid ammonium carbonate (Spray Dried and Solvent 
Extraction) - It has been shown that encapsulation of solid ammonium carbonate 
particles by spray drying and solvent extraction methods resulted in the 
Sample Name Maximum  
Enhancement  
Maximum  
Dose 
Spray Dried 
Solvent Extraction 
Baseline (2.8dB) 
Baseline (2.8dB) 
Upto 1mg/ml 
Upto 1mg/ml 
DL6 
DL25 
15.6dB 
9.1dB 
0.6mg/ml 
0.6mg/ml 
DL25C-0.025 
DL25C-0.05 
DL25C-0.1 
DL25C-2.5 
DL6C 
17.9dB 
19.3dB 
15.3dB 
9.15dB 
12dB 
0.6mg/ml 
0.6mg/ml 
0.6mg/ml 
0.6mg/ml 
0.6mg/ml 
DL25AC4 
DL25AC25 
DL25AC45 
19.5dB 
16.23dB 
8.6dB 
0.03mg/ml 
0.03mg/ml 
0.03mg/ml 
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fabrication of microcapsules with acoustic enhancement values similar to 
baseline, 2.8 dB.  
· Encapsulation of water droplets (Native DL6 and DL25) – An adapted double 
emulsion method produced contrast agents with acoustic enhancements of 9.1 and 
15.6 dB, respectively, results were dependent on the properties of the surfactant 
used (p<0.01).  
· Encapsulation of water droplets and dissolved camphor: DL25C-0.025, DL25C-
0.05, DL25C-0.1 and DL25C-2.5 – Produced contrast agents with acoustic 
enhancements ranging from 9.15 dB to 19.3 dB, results were dependent on the 
amount of camphor encapsulated (p<0.01). 
· Encapsulation of water droplets and dissolved camphor: DL6C – Produced an 
unstable agent that gave an enhancement of ~12 dB. 
· Encapsulation of water droplets, dissolved camphor and dissolved ammonium 
carbonate particles: DL25AC4, DL25AC26 and DL25AC45 – Produced agents 
with acoustic enhancements ranging from 8.6 dB to 19.5 dB, results were 
dependant on temperature of PVA solution used (p<0.01).  
 
 Highest levels of acoustic enhancements were achieved with the DL25C-0.05 
(19.3dB) and DL25AC4 (19.5dB) samples, insonated at 5MHz, at the highest dose within 
the identified dose range (0.6mg/ml and 0.03mg/ml, respectively).  
 Highest level of acoustic enhancement for the lowest dose was achieved with sample 
DL25AC4, 19.5dB at a dose of 0.03mg/ml 
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4.2 CROSS-SECTION OF PLGA CONTRAST AGENT 
Determining the microcapsules internal structure is important for future development 
of the agent as a drug delivery vehicle.  This determination may help explain the drug 
loading and drug release profile.  Obtaining a cross section of a PLGA microcapsule has 
been accomplished in the past [Crotts et al., 1995; Narayan, March 1999]; however, the 
microcapsules in question were ~30mm and ~10mm in diameter, respectively, thirty and 
ten times larger than Phase II agent. The 30mm particles are much larger than Phase II 
agent and handling of the microcapsules is much easier for that reason.  The 10mm 
microcapsules (ten times larger than Phase II agent) were not hollow, making them a 
much more rigid product to work with.  For the reasons stated above obtaining a cross-
section of the hollow, 1mm diameter Phase II agent presented some challenges.  Three 
methods to cross-section the agent were investigated and are presented next.   
 
4.2.1 Embedding in Epoxy and Cross Sectioning 
An initial attempt to cross-section the PLGA contrast agent was done by embedding 
the microcapsules in epoxy and cross sectioning the dried suspension using a silicone 
carbide wheel, as described in Section 3.4.1.  Results were analyzed by inspection of 
scanning electron micrographs (SEM) taken of the sliced epoxy, Fig. 4.23.  What was 
seen in the SEM were intact microcapsules (the objects sitting on the surface of the 
epoxy) and pockets that match the size and morphology of the microcapsules in the 
epoxy surface.  It was hypothesized that as the silicone carbide wheel came in contact 
with the microcapsules, it did not slice them but rather pulled them out of the epoxy and 
created pockets in their place.  The epoxy should have bound the PLGA microcapsules 
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strong enough so as to prevent this from happening.  However it is evident that this was 
not the case.   
As explained previously there is a thin film of PVA on the surface of the 
microcapsules, which may have affected the binding of the microcapsules to the epoxy.  
Additionally, while the silicone carbide wheel was the recommended material/tool for 
slicing polymer and epoxy, it may not have been the optimal choice.   
A diamond knife, a much stronger tool, was hypothesized to be a good replacement 
for the silicone carbide wheel, however, availability and cost were limiting factors in 
testing this hypothesis, and an alternate method was sought out.   
 
4.2.2 Embedding in Epoxy and Polishing 
An attempt to cross-section the PLGA contrast agent was then done by embedding 
the microcapsules in epoxy and polishing that surface, as described in Section 3.4.2.  
SEM of the polished microcapsule/epoxy surface was examined, Fig. 4.24.  Results 
indicated that the microcapsules may have been compacted through the polishing process.  
Further more, it seemed as though the polished debris may have been compressed within 
and between the microcapsules, indicating that the washing phase of the polished 
microcapsule/epoxy surface was not efficient.  This method was determined to be 
ineffective for obtaining a cross-section of the 1mm PLGA contrast agents.    
 
4.2.3 Probe Sonication 
Probe sonication (110 watts at 20kHz for 5 minutes) of the contrast agent was then 
attempted to break open the PLGA agent, method described in Section 3.4.3.  The 
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concern was that this method would cause complete destruction of the microcapsules, 
making it difficult to identify the interior structure of the agent.   
The microcapsules suspended in deionized water without difficulty.  Deionized water 
was used in place of a buffer solution to avoid having salt remains when the insonated 
microcapsules were dried.  Having salt remain may result in difficulty differentiating 
between salt particles and destroyed PLGA particles within an SEM of a dried sample.  
SEM examination of the dried microcapsules indicated that this method was successful in 
breaking open the microcapsules, keeping them intact enough to identify the interior 
structure, Fig. 4.25.  SEM analysis indicates that the microcapsules are not porous but 
rather hollow with very thin (estimated to be 150nm) shells.  This method was concluded 
to be the most effective approach for inspecting the interior of the PLGA agent.   
 
4.3 ULTRASOUND-INDUCED DEGRADATION OF PHASE I AND PHASE II AGENTS 
Degradation studies were carried out on the 1 mm diameter PLGA Phase I and Phase 
II contrast agents, (Section 4.1.3).  In summary, both were shown to be echogenic; 
however, the dose of agent required to give maximum acoustic reflection was found to be 
dependent upon capsule fabrication method (Sections 4.1.3.1 and 4.1.3.2).  Phase II agent 
achieved an acoustic maximum enhancement of up to 25dB in vitro, at a dramatically 
smaller dose, (0.004mg/ml), compared to Phase I agent, 0.6mg/ml.  It was hypothesized 
that the morphology of the two capsule types varied, with those prepared with added 
ammonium carbonate having a much greater porosity, or thinner, more flexible walls. 
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4.3.1 HPLC Method and Standard Curve 
Quantification of lactic and glycolic acid amounts released over time is essential for 
an accurate study of microcapsule degradation.  Only HPLC can quantify lactic and 
glycolic acid amounts present in solution.  Before the start of the degradation study, an 
HPLC method was established to accurately separate, detect and quantify lactic and 
glycolic acid contents present within a solution.  HPLC columns were investigated, the 
Inertsil ODS-3V, 5mm column from Alltech, was found to contain 18% carbon loading 
which gave it good retention of hydrophobic, non-polar agents.  The column separated 
lactic and glycolic acids based on hydrophobicity.  The more hydrophilic glycolic acid 
passed through the column faster, with a retention time around 3 minutes as compared to 
6 minutes for lactic acid.  The mobile phase chosen for the column (as recommended by 
the manufacturer, Alltech) for optimal separation of the two acids was 0.1M ammonium 
dihydrogen phosphate, pH 2.5, with a flow rate of 1.0ml/min.   
Initially a standard curve was constructed using various concentrations of lactic and 
glycolic acids.  The HPLC chromatograph, Fig. 4.26, (area under the curve (AU) verses 
time (minutes)) showed a clear separation of the two acids at all concentrations, with 
glycolic acid showing a very sharp peak at 3.6 min and lactic acid showing a well-defined 
peak at 6.3 min.  Additionally, the chromatograph showed a solvent front ~ 2.9 minutes, 
this may be difficult to identify in Fig. 4.26 due to the large scale.  The results showed a 
linear relationship (r2 = 0.9952 and 0.9997) between the concentrations of lactic and 
glycolic acids, respectively, present and the area under the curve calculated by the HPLC.  
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4.3.2 Degradation Experiment 
Two experimental groups consisting of three samples each were prepared (as 
described in Section 3.6), and are summarized in Table 4.6.  
 
Table 4.6: Degradation Study - Experimental Groups and Samples 
 
Experimental Group Sample Set Ultrasound Frequency 
Phase I-C Control – not exposed to 
ultrasound 
Phase I-5 Insonated at 5MHz 
Group 1 –  
Phase I contrast agent 
(Capsules fabricated by 
encapsulation and 
sublimation of camphor) Phase I-10 Insonated at 10 MHz 
Phase II-C Control – not exposed to 
ultrasound 
Phase II-5 Insonated at 5MHz 
Group 2 –  
(Phase II contrast agent 
Capsules fabricated by 
encapsulation and 
sublimation of 
ammonium carbonate 
and camphor) 
Phase II-10 Insonated at 10 MHz 
 
 
 
Insonated capsules, and non-insonated control capsules were incubated at 37oC and 
sampled at 0, 0.25, 24, 72 and 168 hours.  The chromatographs for aliquots taken at time 
zero were all identical and showed a solvent front between 2.7 to 3.2 minutes but, as 
expected, had no identifiable peaks of either lactic or glycolic acid, (Fig 4.27 shows a 
representative chromatograph from sample Phase I-5).  Representative examples of 
chromatographs from experimental group 1 are shown in Fig. 4.28.  The traces not only 
show individual lactic and glycolic acid peaks as the capsules breakdown over time, but 
also show various peaks from soluble oligomers of lactic and glycolic acid or a mixture 
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of the two.  It is notable that the size of the individual lactic, glycolic and oligomer peaks 
present in sample Phase I-5 (Fig. 4.28B, 4.28E and 4.28H) that was insonated at 5 MHz 
are consistently larger than the peaks present in sample Phase I-10 (Fig. 4.28C, 4.28F and 
4.28I) that was insonated at 10 MHz, which are in turn consistently larger than sample 
Phase I-C (Fig. 4.28A, 4.28D and 4.28G) that were not insonated.  The size and number 
of other breakdown peaks are also larger.  From visual inspection it is possible to 
conclude that the capsules insonated at 5 MHz break down faster and in a different way 
from those insonated at 10 MHz, which in turn break down faster and differently than the 
controls.   
Results obtained of lactic and glycolic acid amounts released for the time of 
degradation are presented and discussed below.  Concentrations for degradation aliquots 
taken at time 168 hours are summarized in Table 4.7.  This table is recommended as a 
reference for the discussions presented next.   
 
Table 4.7: Lactic and Glycolic Acid Concentrations (mmol/mL)  
Released after 168 Hours of the Degradation Study 
 
 
 
 Lactic Acid (mmol/mL) Glycolic Acid (mmol/mL) 
Phase I-C 0.0194 0.0665 
Phase I-5 0.0802 0.1961 
Phase I-10 0.0338 0.0869 
Phase II-C 0.0437 0.1114 
Phase II-5 0.0897 0.2605 
Phase II-10 0.0564 0.2344 
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By quantification (area under the curve compared to standards) of the lactic acid 
content released from control samples and samples insonated at 5MHz and 10 MHz 
(Table 4.7, Fig. 4.29 Phase I contrast agent, and Fig. 4.30 Phase II contrast agent) it is 
clear that more lactic acid was released when the capsules were insonated at 5MHz, (4.1 
and 2.4 times more lactic acid released from Phase I-5 than Phase I-10 and Phase I-C, 
respectively, and 2.1 and 1.6 times more lactic acid released from Phase II-5 than Phase 
II-10 and Phase II-C, respectively, after 168 hours of degradation).  This same trend is 
seen with the amount of glycolic acid released (Table 4.7, Fig. 4.31. and, Fig. 4.32.); with 
3 and 2.3 times more glycolic acid released from Phase I-5 than Phase I-10 and Phase I-
C, respectively, and 2.3 and 1.1 times more glycolic acid released from Phase II-5 than 
Phase II-10 and Phase II-C, respectively, after 168 hours of degradation.   
In further investigating degradation of the capsules in relation to their acoustic 
properties, the break down profiles were compared to the efficiency with which the 
capsules scatter ultrasound (0.004 mg/ml (Phase II agent) required to reach maximum 
enhancement of 25 dB compared to 0.6 mg/ml (Phase I agent)).  Lactic acid contents 
released from the acoustically more efficient Phase II agent, (Phase II-C (Control), Phase 
II-5 (5 MHz) and Phase II-10 (10 MHz)) were 2.3, 1.1 and 1.7 times more, respectively, 
than lactic acid contents released from Phase I agent, (Phase I-C (Control), Phase I-5 
(5MHz) and Phase I-10 (10MHz)).  This can be seen by comparison of Fig. 4.29. (which 
shows lactic acid contents from Phase I-C, Phase I-5 and Phase I-10) and Fig. 4.30. 
(which shows lactic acid contents from Phase II-C, Phase II-5 and Phase II-10).  Glycolic 
acid contents released from the acoustically more efficient Phase II agent, Phase II-C 
(Control), Phase II-5 (5 MHz) and Phase II-10 (10MHz) are also greater (1.7, 1.3 and 2.7 
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times more, respectively) than glycolic acid contents released from the less active Phase I 
agent, Phase I-C (Control), Phase I-5 (5MHz) and Phase I-10 (10MHz).  These results 
can be seen by comparison of Fig. 4.31. (which shows glycolic acid contents from Phase 
I-C, Phase I-5 and Phase I-10) and Fig. 4.32. (which shows glycolic acid contents from 
Phase II-C, Phase II-5 and Phase II-10).  The more acoustically efficient agent was 
hypothesized to have a thinner shell.  This would make it more susceptible to break 
down.  This process is further enhanced with ultrasound.  
It was also observed that the amount of glycolic acid released from any one sample, 
Phase I-C, Phase I-5, Phase I-10, Phase II-C, Phase II-5 and Phase II-10, is 3.4, 2.4, 2.6, 
2.5, 2.9, and 4.2 times more, respectively, in comparison to the amount of lactic acid 
released from the same sample.  This can be seen by carefully comparing lactic acid 
content of Phase I-C, Phase I-5 and Phase I-10, (Fig. 4.29) with their glycolic acid 
content (Fig. 4.31), and by comparing lactic acid content of Phase II-C, Phase II-5 and 
Phase II-10,  (Fig. 4.30) with their glycolic acid content (Fig. 4.32).  The explanation 
behind these results can be understood by comparing the structures of glycolic and lactic 
acid molecules (Fig. 2.1).  The lactic acid molecule has a bulky methyl group that is not 
present in the glycolic acid molecule.  This methyl group makes it a more hydrophobic 
molecule, and as explained before, this makes it relatively difficult for water to attack, as 
compared to glycolic acid.  Thus, glycolic acid breaks down at a quicker rate in an 
aqueous solution than lactic acid.   
It is evident from the results obtained that the rate of degradation was dependent not 
only on exposure to ultrasound but also to the frequency at which the microcapsules were 
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insonated, and the method by which the capsules were fabricated.  This information is 
important for understanding future work on the ultrasound triggered drug delivery.   
 
4.4 ATTENUATION STUDIES 
Loss of acoustic energy from a sound beam is referred to as attenuation [Kinsler, 
1982].  Acoustic energy is lost at a faster rate in a fluid that contains particles than a 
homogenous fluid that does not.  Higher levels of attenuation are seen in fluids 
containing hollow microcapsules (contrast agents) than those containing solid particles.  
This is due to the compression and expansion of the contrast agents, which leads to loss 
of energy by the sound wave.  A more valuable aspect of contrast agents with respect to 
attenuation is their scattering effect.  Each hollow microcapsule removes and reradiates a 
portion of the incident energy.  Contrast agents with a resonance frequency equal to that 
of the acoustic wave will have the greatest scattering effect [Kinsler 1982].   
An in vitro attenuation study of Phase II contrast agents (PLGA 50:50) has been 
carried out. Methods are described in Section 3.3.1.3.  Results show that the agent has a 
resonance frequency (that frequency at which attenuation is the highest) between 1.78 
and 1.88 MHz, Fig. 4.33.   
Phase II agent was then fabricated with different polymers, PLGA 75:25, PLGA 
85:15 and PLA.  The attenuation spectrum of these agents was constructed, Fig. 4.34, 
4.35 and 4.36, respectively.  The resonance frequency results obtained, 2.28MHz, 
1.78MHz and 2.28 MHz, respectively for Phase II PLGA (75:25), Phase II PLGA (85:15) 
and Phase II PLA, were in close proximity to those reported with the Phase II PLGA 
(50:50) agent. These results are summarized in Table 4.8.  Dr. Flemming Forsberg, 
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Raymond Ro and Dr. Raghue Basude have provided assistance for all in vitro attenuation 
experiments.   
 
Table 4.8: Summary of Resonance Frequency for  
Different Ultrasound Contrast Agents    
 
 
 
Contrast Agent Resonance Frequency (MHz) 
Phase II PLGA (50:50) 1.78 - 1.88 
Phase II PLGA (75:25) 2.28 
Phase II PLGA (85:15) 1.78 
Phase II PLA 2.28 
 
 
 
4.5 IN VIVO STUDIES    
In vitro acoustic properties of Phase II PLGA (50:50) contrast agent were studied 
(Section 4.1.3.2.3).  The results showed enhancements of up to 24 dB for a small 
concentration, 4mg/mL.  In vivo acoustic studies were carried out with the agent, methods 
described in Section 3.3.2.   
 
4.5.1 Dose Response 
Phase II contrast agent was prepared and taken as a dry powder to Thomas Jefferson 
University Hospital, (where all in vivo experiments were performed).  The agent (0.04g 
per vial) was reconstituted in 1mL of saline prior to injection.  In vivo dose response was 
carried out by the method described in Section, 3.3.2.1.    
Three in vivo dose response curves (1, 2 and 3) were constructed in different rabbits, 
Fig. 4.37, 4.38 and 4.39, respectively.  In vivo studies to construct dose response curves 
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were performed on two separate days.  Dose response curves 1 and 2 (Fig 4.37 and 4.38, 
respectively) were constructed on one day and studies for dose response curve 3 were 
performed on another day.  Acoustic enhancements were seen in all rabbits.  However, 
results varied from experiments carried out on the two separate days, with lower 
enhancements of 15dB seen with dose response curves 1 and 2 in comparison to the 24 
dB enhancement recorded with dose response curve 3, when insonated at 10 MHz for a 
dose of 0.1 mL/Kg.  Results of curve response dose 3 paralleled results of the vitro dose 
response studies presented previously.       
Investigations to determine the reason for these differences were not carried out, as 
lower enhancement values of 15dB were not observed for studies reported thereafter 
[Lathia et al, 2003b].  
 
4.5.2 No Sign of Animal Distress after Injection of Phase II PLGA Contrast Agent 
The number of injections per rabbit were recorded (~24) and the rabbits were 
monitored for distress by Jefferson University medical staff.  Even after the 24th injection 
of agent, the rabbits (as reported) did not show any adverse side effects.  This was not at 
all a surprise.  As previously explained, the novel fabrication process of these PLGA 
contrast agents led to the development of 1mm hollow PLGA microcapsules with a 
narrow size distribution.  The smallest capillaries are those of the pulmonary system, 7-
8mm.  It is essential that the contrast agent be below that diameter to ensure easy passage 
through the circulatory system, and prevent an embolism.  These capsules are well below 
that limit and as shown are ideal for intravenous injection.   
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4.5.3 Power Doppler 
Further in vivo studies were conducted. Power Doppler images of the rabbit kidney 
were taken pre and post injection of 0.15mg/mL of Phase II agent, Fig 4.40.  
 
4.5.4 Time Response 
While in vivo dose response results (dose response curve 3) have mimicked in vitro 
results, the time response studies presented a different case.  In vitro time response 
studies indicated a loss of only 4 dB in 20 minutes.  In vivo results obtained presented a 
very different scenario, with complete loss of signal within 30-45 seconds from the time 
of initial visualization.   
The pH (7.4) and pressure within the in vitro acoustic tank (at the level of reading) 
and within the body were common factors and were not tested.  The differing elements, 
lack of plasma and blood components as well as a lower temperature (25°C) of the in 
vitro buffer were tested.  The buffer solution was replaced with serum and the time 
response in vitro was tested, results were unaltered. The 12°C difference between the in 
vitro and the in vivo conditions was tested and found to have a statistically significant (2-
way ANOVA, p<0.01) effect on the acoustic properties.  In vitro studies were carried out 
at both 25°C and 37°C, Fig 4.41.  At 25°C the agent lasted up to 20 minutes with a 
minimal loss of signal (4dB), in comparison to 37°C where the signal drops close to base 
line with in the first 5 minutes.   
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4.5.5 A Hydrophobic Polymer for Fabrication of Phase II Contrast Agent  
Investigations of PLGA’s mechanical and material properties have been previously 
reported [Callister 1994; Billmeye 1984, Ellis 2000].  The copolymer PLGA is composed 
of lactic acid and glycolic acid.  Both poly lactic acid (PLA) and poly glycolic acid 
(PGA) are thermoplastic polymers.  Thermoplastic is a property that gives a material its 
ability to become soft when heated and re-harden when cooled without any appreciable 
change to its properties.  Additionally PLGA is an amorphous polymer.  Amorphous 
refers to the random alignment of the polymer chains.  This can be compared to a 
crystalline structure where the polymer chains are more rigidly aligned.  Addition of 
glycolic acid to the copolymer makes it more amorphous.  The glass transition 
temperature of amorphous polymers refers to that temperature at which the structure 
transforms from a rigid-like material to a rubber-like characteristic.  The glass transition 
temperature for poly glycolic acid (PGA) is lower than that for poly lactic acid (PLA), 
(generally 35°C - 45°C and 55°C - 64°C, respectively, dependant on molecular weight).  
The glass transition temperature is shown to decrease with increased amounts of glycolic 
acid in the co-polymer, Table 4.9.  
 
Table 4.9: Polymer Formulation and Glass Transition Temperature (°C) 
 
 
Polymer Formulation (MW-kd) Glass Transition Temperature (°C)  
50% d/l lactide/ 50%glycolide (47) 43-48 
65% d/l lactide/ 35%glycolide (51) 45-50 
75% d/l lactide/ 25%glycolide (48) 48-53 
85% d/l lactide/ 15%glycolide (56) 50-55 
100% d/l lactide (56) 50-55 
Source: Alkermes Inc 
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The glass transition temperature for 50:50 PLGA is 43-48°C.  This explains why at 
25°C Phase II (50:50) agent was not affected, but at 37°C it was.  At higher temperatures 
(closer to 43°C) the polymer softens and the microcapsules experience an enhanced 
hydration effect.   
To alter this effect chain flexibility was decreased.  Altering chain flexibility was 
possible by increasing the ratio of lactic acid molecules present in the copolymer. Lactic 
acid contains a bulky methyl group that is not present in glycolic acid.  The introduction 
of bulky groups to the polymer chain allows it to resist rotation.  A graphic diagram is 
presented to illustrate this concept, Fig. 4.42 (reference to Fig. 2.1 is essential for PLGA 
chemistry).  The presence of the methyl group also makes the lactic acid a more 
hydrophobic molecule.  It was hypothesized that fabrication of Phase II contrast agent 
with a more hydrophobic polymer and one with a higher glass transition temperature (one 
that contains a higher content of lactic acid molecules (like PLGA 75:25, 85:15 or even 
PLA)) in place of PLGA 50:50 would better protect the capsules from the surrounding 
fluid, and prolong the acoustic properties of the contrast agent.     
Phase II agents have been fabricated with PLGA 75:25, 85:15 and PLA.  In vitro 
temperature studies proved this hypothesis to be accurate [Lathia et al., 2002; Craine et 
al., 2003].  No significant change was seen in acoustic enhancement properties of the 
agents tested at 25°C compared to 37°C.  In vivo Doppler and time response studies were 
also carried out with Phase II agents prepared with the more hydrophobic polymers 
[Lathia et. al. 2003].  In vivo Doppler studies with Phase II PLGA (75:25), Phase II 
PLGA (85:15) and Phase II PLA, showed acoustic enhancements similar to that achieved 
with Phase II PLGA (50:50) contrast agent.  In vivo time response of the more 
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hydrophobic contrast agents prolonged stability and enhancements lasted from 3-11 
minutes.  All in vivo experiments were carried out at Thomas Jefferson University 
Hospital.   
It was concluded that fabrication of Phase II contrast agents with a more hydrophobic 
polymer (PLGA 75:25, PLGA 85:15 and PLA) prolongs the lifespan of the agent at 
37°C.  
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Figure 4.1: Scanning electron micrograph (SEM) of spray dried microcapsules, at a 
magnification of 2000X.  Size bar denotes 10mm. 
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Figure 4.2: Scanning electron micrograph (SEM) of solvent extraction capsules, at a 
magnification of 1,000X.  Size bar denotes 10mm. 
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Figure 4.3: Horiba size distribution analysis of Spray Dried microcapsules. Mean 
diameter is 9.5mm 
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Figure 4.4: Horiba size distribution analysis of Solvent Extraction microcapsules.  Mean 
diameter is 10.3mm 
 
 
 
 
 
 
  
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Scanning electron micrograph showing the surface morphology of the RG133 
capsules prepared with PVA MW 133,000.  A) Magnification at 17,000X 
(size bar 1 µm). B) Magnification at 5,000X (size bar 1 µm). 
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Figure 4.6: Scanning electron micrograph showing the surface morphology of the RG25 
capsules prepared with PVA MW 25,000.  A) Magnification at 6,000X (size 
bar 1 µm). B) Magnification at 2,000X (size bar 10 µm). 
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Figure 4.7: Scanning electron micrograph showing the surface morphology of the RG6 
capsules prepared with PVA MW 6,000.  A) Magnification at 6,000X (size 
bar 1 µm). B) Magnification at 2,000X (size bar 10 µm) 
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Figure 4.8: Scanning electron micrograph showing the surface morphology of the DL25 
Native agent prepared with PVA MW 25,000, Magnification at 6000X (size 
bar 1 µm).  
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Figure 4.9: Scanning electron micrograph showing the surface morphology of the DL6 
Native agent prepared with PVA MW 6,000, Magnification at 3000X (size bar 
10 µm). 
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Figure 4.10: Cumulative dose response curves of Native agent prepared with DL 3A 
polymer and 6,000MW PVA (DL6) ¦  and 25,000 MW PVA (DL25) ? . 
(n=3, ± standard error from the mean) 
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Figure 4.11: Schematic representation of hypothetical formation of the Native agent 
through the double emulsion process  
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Figure 4.12:  Horiba size distribution analysis of Native agent (DL25).  Mean distribution 
of agent 1.2mm. 
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Figure 4.13: Schematic representation of the hypothetical formation of Phase I agent 
through the adapted double emulsion process of encapsulating and later 
subliming water and camphor 
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Figure 4.14: Cumulative dose response curves of capsules prepared with the DL 3A 
polymer, 25000MW PVA and different camphor amounts, 0.0g ¦  (DL25), 
0.025g¨(DL25C), 0.05g ?  (DL25C), 0.1g X (DL25C) and 2.5g ?  
(DL25C). (n=3, ± standard error from the mean) 
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Figure 4.15: Time response curve (20 minutes) for enhancement stability of Phase I agent 
(DL25C) prepared with the DL 3A polymer, 25,000MW PVA and 0.05g of 
camphor, at a 0.4mg/ml dose.  Contrast agent suspension insonated at 5 
MHz.  (n=3, ± standard error from the mean) 
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Figure 4.16: Schematic representation of the hypothetical formation of Phase II agent 
through the adapted double emulsion process of encapsulating and later 
subliming water, camphor and ammonium carbonate  
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Figure 4.17:  Horiba size distribution analysis (number %) of Phase II agent (DL25AC) 
prepared with the DL3A polymer, 25,000MW PVA, 0.05g of camphor and 
4% ammonium carbonate aqueous solution. Size distribution shows 99.6% 
of capsules lie between 0.4 to 4.0µms and have an average diameter of 
1.210 µms. 
Mean Diameter 1.210mms 
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Figure 4.18:  Coulter analysis - Size distribution of Phase II agent (prepared with the 
DL3A polymer, 25,000MW PVA, 0.05g of camphor and 4% ammonium 
carbonate aqueous solution). Size distribution shows an average diameter 
of 1.24 µm. 
 
Mean Diameter 1.242mms 
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Figure 4.19:  Scanning electron micrograph showing the surface morphology of Phase II 
agent (DL25AC) prepared with the DL 3A polymer, 25,000MW PVA, 
0.05g of camphor and 4w/v% ammonium carbonate aqueous solution.  
(Size bar denotes 1 µm).   
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Figure 4.20:  Non-cumulative dose response of Phase II agent (DL25AC) prepared with 
the DL 3A polymer, 25,000MW PVA (temperature varied), 0.05g of 
camphor and 4% ammonium carbonate aqueous solution.  The agent was 
insonated at 5MHz.  Three PVA temperatures tested, 4°C ? , 26°C ¨ and 
45°C¦ . (n=3, ± standard error from the mean) 
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Figure 4.21: Non-cumulative dose response curve of capsules (DL25AC) prepared with 
the DL3A polymer, 25,000MW PVA, 0.05g of camphor and 4wt/vol% 
ammonium carbonate aqueous solution.  Capsule suspension insonated at 
2.25¨, 5¦ , 7.5? and 10?  MHz.  (n=3, ± standard error from the mean) 
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14
Concentration (ug/ml)
E
n
h
an
ce
m
en
t 
(d
B
)
 
  
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Time response curve (20 minutes at 25 °C) for enhancement stability of 
Phase II agent (DL25AC) prepared with the DL3A polymer, 25,000MW 
PVA, 0.05g of camphor and 4% ammonium carbonate aqueous solution, at a 
0.002mg/ml dose.  Agent suspension insonated at 5 MHz.  (n=3, ± standard 
error from the mean) 
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Figure 4.23: Scanning electron micrograph (SEM) of a cross section of epoxy with 
embedded PLGA contrast agent. Dried contrast agent /epoxy mixture cross-
sectioned with a silicone carbide wheel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
118 
 
 
 
 
 
 
 
 
 
Figure 4.24: Scanning electron micrograph (SEM) of a polished surface of epoxy with 
embedded PLGA contrast agent. 
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Figure 4.25: Scanning electron micrograph (SEM) of PLGA contrast agent broken open 
by probe sonication 
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Figure 4.26:  HPLC chromatograph showing the clear separation of lactic and glycolic 
acids at different concentrations.  Glycolic acid is extracted at 3.6 min and 
lactic acid is extracted at 6.3 min.  Peaks for glycolic and lactic acid 
represent 0.132, 0.099, 0.066, 0.033, 0.013, and 0.111, 0.083, 0.0556, 0.028, 
0.0111 micromoles /ml respectively. 
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Figure 4.27:  HPLC chromatograph of sample Phase I-5 (aliquot taken upon immediate 
suspension of microcapsules in buffer (before insonation) showing a solvent 
front between 2.7 to 3.2 min, (no identifiable peaks of either lactic or 
glycolic acid can be seen). 
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Figure 4.29:  Amount (umol/ml) of lactic acid released over time from Phase I contrast 
agent (0.34g) (microcapsules fabricated by encapsulation and later 
sublimation of camphor) (? Control not insonated (Phase I-C), ¨insonated 
at 5 MHz (Phase I-5), ·insonated at 10MHz (Phase I-10)). (n=9, ± standard 
error from the mean) 
  
 
 
 
0.0000
0.0500
0.1000
0.1500
0.2000
0.2500
0.3000
0 20 40 60 80 100 120 140 160 180
Time (Hours)
C
o
n
ce
n
tr
at
io
n
 (
u
m
o
l/m
L
)
  
124 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30:  Amount (umol/ml) of lactic acid released over time from Phase II contrast 
agent (0.34g)(microcapsules fabricated by encapsulation and later 
sublimation of ammonium carbonate and camphor) (? Control not 
insonated (Phase II-C), ¨insonated at 5 MHz (Phase II-5), ·insonated at 
10MHz (Phase II-10)). (n=9, ± standard error from the mean) 
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Figure 4.31:  Amount (umol/ml) of glycolic acid released over time from microcapsules 
(0.34g) fabricated from encapsulation and later sublimation of camphor 
(? Control not insonated (Phase I-C), ¨insonated at 5 MHz (Phase I-5), 
·insonated at 10MHz (Phase I-10)). (n=9, ± standard error from the mean) 
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Figure 4.32:  Amount (umol/ml) of glycolic acid released over time from microcapsules 
(0.34g) fabricated by encapsulation and later sublimation of ammonium 
carbonate and camphor (? Control not insonated (Phase II-C), ¨insonated 
at 5 MHz (Phase II-5), ·insonated at 10MHz (Phase II-10)). (n=9, ± 
standard error from the mean) 
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Figure 4.33:  Attenuation with frequency for Phase II PLGA (50:50) contrast agent.  Data 
was obtained within the –6dB bandwidth of the transducers.  Additionally 
extended bandwidth data from the 5MHz transducer is shown. 
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Figure 4.34:  Attenuation with frequency for Phase II PLGA (75:25) contrast agent.  Data 
was obtained within the –6dB bandwidth of the transducers.  Additionally 
extended bandwidth data from the 5MHz transducer is shown
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Figure 4.35:  Attenuation with frequency for Phase II PLGA (85:15) contrast agent.  Data 
was obtained within the –6dB bandwidth of the transducers.  Additionally 
extended bandwidth data from the 5MHz transducer is shown. 
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Figure 4.36:  Attenuation with frequency for Phase II PLA contrast agent.  Data was 
obtained within the –6dB bandwidth of the transducers.  Additionally 
extended bandwidth data from the 5MHz transducer is shown. 
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Figure 4.37:  In vivo dose response from PLGA (50:50) contrast agents (experiment 1, 
n=3, ± standard error from the mean).  In vivo studies carried at Thomas 
Jefferson University Hospital on New Zealand white rabbits. 
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Figure 4.38:  In vivo dose response from PLGA (50:50) contrast agents (experiment 2, 
n=3, ± standard error from the mean). In vivo studies carried at Thomas 
Jefferson University Hospital on New Zealand white rabbits. 
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Figure 4.39:  In vivo dose response from PLGA (50:50) contrast agents (experiment 3, 
n=3, ± standard error from the mean).  In vivo studies carried at Thomas 
Jefferson University Hospital on New Zealand white rabbits. 
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Figure 4.40:  Power Doppler Enhancement (boxed area) of rabbit kidney.  A) Pre-
injection of PLGA contrast agent. B) Post-Injection of 0.15ml/kg of PLGA 
contrast agent.  (In vivo studies carried out at Thomas Jefferson University 
Hospital on New Zealand white rabbits).   
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Figure 4.41: Temperature study of in vitro time response curve (20 minutes) for 
enhancement stability of Phase II agent (PLGA 50:50), at a 0.002mg/ml 
dose.  Contrast agent suspension insonated at 5 MHz.  Temperature study 
carried out at 25°C (¨) and 37°C (·) (n=3, ± standard error from the mean) 
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Figure 4.42: Schematic representation of the “hydrophobic protective qualities” of the 
lactic acid methyl group in the fabrication of Phase II contrast agent with 
different ratios of lactic and glycolic acid (PLGA 50:50, 75:25, 85:15 and 
PLA). 
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5. THE FUTURE OF THESE PLGA CONTRAST AGENTS –  
PRELIMINARY STUDIES 
 
 
As explained in Chapter 1 of this thesis, the long-term goals of this project are to use 
these contrast agents as targeted drug delivery vehicles.  The two aspects, drug delivery 
and targeting were both explored separately.  Fabrication of nano particles from 
previously reported protocols is also reported.  Preliminary results are presented below 
for all three sections.  
 
5.1 DRUG DELIVERY 
The field of drug delivery is vast and very diverse.  The topic “drug delivery” could 
potentially mean anything that involves the delivery of drugs, including drug delivery 
devices, those devices such as inhalers that are needed to deliver a drug.  It could also 
mean oral, inhaled, transdermal, injected (intravenous, subcutaneous or intramuscular) or 
even implantable drug delivery systems.  These systems can be described as a drug 
incorporated within a matrix from which the drug is slowly disassociated or released. The 
matrix could be composed of a biodegradable or a non-biodegradable material.  Drug 
release may be controlled over a specified time period and even perhaps at a specific 
location.   
This project focuses on a systemic drug delivery system in which the matrix is a 
biodegradable polymer, PLGA or PLA, contrast agent (described in Chapter 4).  
Systemic delivery of a drug incorporated within the contrast agent has two major 
advantages: (1) the drug is not available to the body until it is disassociated from the 
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microcapsule and (2) identifying the location of the drug within the body can be 
accomplished by locating the agent via ultrasound imaging.   
The drug can be incorporated within the PLGA/PLA contrast agent in three ways: 
(1) Encapsulation 
The drug maybe encapsulated within the microcapsule as shown in Fig 5.1A.  This 
can be accomplished by dissolving a hydrophilic drug in the first water phase, just as 
encapsulation of dissolved ammonium carbonate was accomplished (Fig. 5.1).  It is 
hypothesized that some of the drug will be in the shell and some will reside in the center 
of the microcapsule.  The amount of drug to be encapsulated is limited by the acoustic 
properties of the microcapsules, if too much (exact quantity not yet identified) is 
encapsulated then the agent would lose its hollowness and thus its acoustic enhancement 
properties. Encapsulating the drug within a polymeric shell protects it from the body’s 
physiological surroundings. 
The drug may be released by one of three mechanisms, microcapsule destruction, 
diffusion/natural degradation and diffusion/enhanced degradation. Bursting of the 
microcapsule can be accomplished by insonation with low frequency ultrasound, 
(preliminary experiment used a frequency of ~50MHz for the destruction of 
micrcapsules, this is discussed in section 5.1.1.3).  Bursting of the microcapsule would 
result in immediate bulk delivery of the drug.  Diffusion of the drug out of the 
microcapsule accompanied by natural degradation of the polymer would result in slow 
release of the drug from the microcapsule.  Enhanced degradation of the microcapsule by 
use of ultrasound (Section 4.3) would result in faster drug release in comparison to 
diffusion (as a result of natural degradation).   
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(2) Attachment  
The drug can be chemically bound to the surface of the contrast agent, Fig 5.1B 
(Mechanism of drug attachment to the contrast agent could be accomplished by a method 
similar to that described in Section 5.2). This attachment is generally strong (the drug can 
not be shaken off the contrast agent, but rather would require additional energy to break 
the bond and disassociate the drug from the agent).  Breaking this bond with ultrasound 
energy has not yet been investigated.  The amount of drug attached would be limited by 
the surface capacity of the contrast agent.   
 
(3) Adsorption 
The drug may be adsorbed onto the surface of the contrast agent, Fig 5.1C.  This 
adsorption is generally a weak bond between the drug and the polymeric agent.  This 
method would hypothetically allow the drug to be easily removed from the surface of the 
agent.  
 
5.1.1 Preliminary Studies 
Deciding which drug incorporation method (described in Section 5.1) was to be 
investigated was dependent upon the therapeutic use of the drug.  The end goal is to use 
the contrast agent as a targeted therapeutic system for delivering anticancer agents to 
tumor sites.   The most ideal model would be that which delivers the largest amount of 
therapeutic agent in the shortest amount of time, thus having the strongest effect.  
Preliminary experiments were carried out to identify parameters that may have an effect 
on the drug loading process.   
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Native agent was used for preliminary drug delivery studies (these studies were 
carried about prior to development of Phase I and Phase II contrast agents).  Additionally 
a preliminary drug loading experiment was carried out on Phase II agent.  
 
5.1.1.1 Adsorption and Release of Doxorubicin from Native Agent – (Insonated at 
5MHz) 
 
Preliminary experiments were carried out to demonstrate the potential use of Native 
agent DL25 to carry and deliver Doxorubicin.  Native agent had a thin PVA layer on its 
surface, which allowed it to suspend easily in the aqueous solution without any 
aggregation tendencies.  Additionally Native agent DL25 demonstrated acoustic 
enhancements up to 9.1 dB.  
Doxorubicin (naturally red in color) was adsorbed on the surface of Native agent 
DL25.  Briefly, microcapsules (1g) were suspended in 10mL of deionized water.  
Doxorubicin (200mL from a 1mg/mL stock solution) was dissolved in the agent 
suspension (for a total concentration of 0.2mg of Doxorubicin/ g of microcapsules).  The 
suspension was stirred at room temperature for 23 hours.  The agent was washed with 
PBS (pH 7.4), centrifuged and freeze dried.  The agent had a strong red color, which 
indicated that the adsorption process was successful (quantification of drug loading is 
discussed in Section 5.1.1.4).   
A drug release study was carried out with the doxorubicin incubated microcapsules.  
Briefly, 0.08g of microcapsules were placed in 100mL of PBS (pH 7.4), and then 
immediately divided into two sample vessels of 50mL each, one labeled control and one 
labeled experimental.  The control vessel was stirred for 20 minutes and not subjected to 
ultrasound.  The experimental vessel was stirred and insonated at 5MHz for 20minutes in 
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the in vitro acoustic set-up, Fig. 3.1.  Aliquots were taken out at 5 different time intervals, 
0 (immediately after the microcapsule suspension was divided into the two vessels, prior 
to stirring or insonation of either the control or the experimental vessel), 5, 10, 15 and 20 
minutes.  Fluorescence level in the aliquots was analyzed by a fluorimeter (Photon 
Technology International, NJ), and amount of doxorubicin released was quantified, Fig. 
5.2. 
Results showed an initial burst of 0.07mg of doxorubicin /g of microcapsules when 
the loaded microcapsules were suspended in PBS.  Results also showed a statistically 
significant (T-Test, p<0.05) increase (1.96, 2.37, 2.27, and 2.23 times more for the 
insonated than the control at time intervals 5, 10, 15, and 20 minutes, respectively) in the 
amount of drug released from the insonated sample in comparison to the stirred sample.  
These preliminary results indicated that the amount of adsorbed drug released from 
the Native agent DL25 can be increased by exposure of the agent to ultrasound (at 
5MHz).  Further investigation of this process is required to reach an optimal state for 
incubation as well as release, including elimination of the initial burst effect.   
 
5.1.1.2 Adsorption of Doxorubicin and FITC-BSA – pH study 
Drug, incubation, and wash pH were hypothesized to have an effect on drug 
adsorption.  To compare two drugs with two different incubation pH levels the following 
experimental design matrix was set-up, Table 5.1.   
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Table 5.1: Experimental Design Matrix – Drug Delivery Study:  
Comparison of Two Drugs and Two Incubation pH Levels. 
 
 
 
 
 
 
 
 
 
 
 
Native agent was incubated with either Doxorubicin or FITC-BSA.  Briefly the 
microcapsules were suspended in 10mL of deionized water (pH adjusted to either 4.94 or 
2.78), and 200mL of drug was added to the suspension.  The 4.94 pH level was chosen 
because it was same pH as the deionized water used for the wash.  The 2.28 pH was 
chosen to test the effect of a “more” acidic pH, exact level was chosen at random.  The 
suspension was stirred overnight for 20 hours at room temperature.  The microcapsules 
were centrifuged (15°C for 5min at 5,000xg) and washed with deionized water (pH 4.94).  
It was suspected that there might be a relationship between the pH of the deionized water 
used for the incubation process and the pH of the deionized water used for the wash 
process.  Native-Dox-5 and Native-BSA-5 were both incubated and washed with 
deionized water of the same pH (4.95).  Native-Dox-3 and Native-BSA-3 were washed 
with deionized water of a higher pH (4.95) then that in which they were incubated (2.78).   
Visual observations of Native-Dox-5 and Native-Dox-3 throughout the different 
phases of the incubation process (pre and post the wash phase, and after freeze drying) 
led to the conclusion that incubation of the agent in deionized water adjusted to pH 4.94 
Sample Name Incubation pH  Drug Adsorbed 
Native-Dox-5 4.94 Doxorubicin 
Native-Dox-3 2.78 Doxorubicin 
Native-BSA-5 4.94 FITC-BSA 
Natvie-BSA-3 2.78 FITC-BSA 
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had a much more profound red color than the agent incubated in deionized water adjusted 
to pH 2.78.  With respect to doxorubicin, this concludes that incubation and washing of 
the Native agent with deionized water of pH 4.94 may be more effective than incubation 
with deionized water of pH 4.94 and washing with deionized water of pH 2.78.   
Although it was hypothesized that both the water soluble drugs chosen (Doxorubicin 
and BSA) would yield similar conclusions, it was found that incubation of Native agent 
with BSA presented some challenges.  Centrifugation of Native-BSA-5, at the end of the 
incubation process, led to a strong yellow film sitting on top of the pellet of settled 
microcapsules, which had a very light yellow color to them.  The isoelectric point (pI) of 
BSA is ~ 4.7.  The isoelectric point is the pH at which the molecule carries no net charge. 
It may be that incubation at a pH (4.94) similar to that at which the molecule is neutral 
may not allow it to adsorb onto the surface of the charged Native agent.   
This yellow film was not seen with the Native-BSA-3 sample, which resulted in 
uniform yellow microcapsules.  The surface morphology of these agents without drug, 
Fig. 5.3A, was compared to Native agent (from the same preparation) with drug, Fig. 
5.3B.  Analysis concluded that drug adsorption through the incubation process described 
did not alter the surface morphology of the agent.   
These preliminary experiments led to the conclusion that incubation and wash pH 
play a critical role in the drug loading process.  The incubation and wash pH were found 
to be drug dependant.  Results varied from one drug to the next.  It was additionally 
concluded that the incubation process did not have a noticeable effect on the surface 
morphology of the microcapsules.   
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These conclusions were based on preliminary experiments and only on visual 
observations.  Quantification of drug loading amounts has been addressed (Section 
5.1.1.4.   
 
5.1.1.3 BSA Encapsulated Within Native Agent and Released by Insonation at 47kHz 
Encapsulation of a drug within a contrast agent and use of low frequency ultrasound 
(47 kHz) to release the drug by destruction of the microcapsule was investigated.  This 
experiment was carried out with Dr. Vladimir Genis (Drexel University), who provided 
all transducers and relevant acoustic support.   
The preparation protocol for the fabrication of Native agent was modified to fabricate 
Native-BSA-Eencap, which encapsulated FITC-BSA within the contrast agent.  Briefly 
0.5g of PLGA (4A) was dissolved in 10mL of methylene chloride and probe sonicated 
with 1mL of 5mg/mL BSA solution.  The emulsion was homogenized in 50mL of a 
5w/v% PVA solution for 5min at 9,500rpm and poured into 100mL of 2% isopropanol 
solution.  The sample was washed, centrifuged and freeze dried as explained in Section 
3.2.1.  A control sample Native-BSA-Cencap was fabricated in a similar manner with one 
difference, probe sonication was carried out with 1mL of deionized water instead of 1mL 
of 5mg/mL BSA solution.   
Upon inspecting the dried agents, observations were reported and summarized in 
Table, 5.2.   
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Table 5.2: Native Agent Used for BSA Encapsulation 
 
 
 
 
 
 
 
 
Both the Native-BSA-Eencap and Native-BSA-Cencap, nicely dispersed upon 
suspension in an aqueous solution, aggregation was not experienced.  
The Native-BSA-Eencap microcapsules had a (119%) yield higher than the amount of 
polymer used in the fabrication process.  This weight difference could partially be a result 
of the encapsulated drug.  The Native-BSA-Cencap microcapsules had a yield of 80.8%.      
A drug release study was carried out using a 44-1 probe 47kHz transducer (with a 
displacement amplitude of 5mm).  Briefly 0.1g of Native-BSA-Eencap was suspended in 
25mL of PBS in a 50mL beaker.  Two sample sets, Native-BSA-Eencap-INSON and 
Native-BSA-Eencap-CONT, were prepared.  Native-BSA-Eencap-INSON samples were 
insonated at 47 kHz pulsed (2 seconds on and 5 seconds off (duty cycle of 28.5%)) 
ultrasonic wave of amplitude 5mms from an ultrasound probe that was placed directly 
into the PBS solution, just high enough from the base of the beaker such that it would not 
disrupt the stir bar.  The probe was connected to an ultrasonic therapy apparatus, which 
supplied its power and indicated time, frequency and amplitude of the wave generated.  
Native-BSA-Eencap-CONT samples were not exposed to ultrasound energy but were 
continuously stirred for 35 minutes.   
Sample Name Emulsified with Aggregation 
Tendencies  
Yield 
Native-BSA-Eencap 1mL of 5mg/mL BSA None 119% 
Native-BSA-Cencap 1mL of Deionized Water None 80.8% 
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Aliquots of 1 mL each were taken at 4 time intervals, 0 min (immediately upon 
suspension of microcapsules in PBS) (0 min exposure to ultrasound), 12.25 min (3 min 
exposure to ultrasound), 22.75 min (6 min exposure to ultrasound), and 33.25 min (10 
min exposure to ultrasound).  The aliquots were centrifuged for 10 min (using an 
Eppendorf centrifuge 5415 C) at 10,000xg, to collect the PBS with released BSA.  The 
BSA was detected in the PBS solution by a detergent compatible protein assay from Bio-
Rad.  The light absorption was read on a Hitachi U-2000 spectrophotometer at a 
wavelength of 750nm.  Each experiment was repeated three times and ± standard error 
from the mean were plotted, Fig. 5.4.   
Both samples had an initial burst of approximately 0.7mg of drug, (drug released 
immediately upon suspension of the agent in a buffer solution).  The percent of BSA 
loaded could not accurately be determined (Section 5.1.1.4). However it can be assumed 
that it is no lower than 66% (100% loading is 5mg of BSA, release from Native-BSA-
Eencap-INSON at time interval 33.25min is 3.83mg) and no higher than 100%.   This is 
about 14% - 18% of the total loaded amount, (within the assumed loading range of 100% 
- 66%, respectively).   
 Insonated samples were statistically different (T-Test, p< 0.05) than the stirred 
samples gaving 1.5, 1.64 and 1.4 times more drug release at time intervals of 12.25, 22.75 
and 33.25min, respectively.   
 This preliminary experiment that encapsulated a drug and released it by use of low 
frequency ultrasound is promising, however may certainly be improved upon.  A more 
rigorous wash process should be investigated to reduce or even eliminate the initial burst 
effect.  Release of encapsulated drug by use of low frequency ultrasound from within the 
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more echogenic Phase II agent (described in Section 4.1.3.2) may have a more enhanced 
release profile (in comparison to Native agent used in this experiment).  This is expected 
because the morphology of the Phase II agent is different (thinner shell) than that of the 
Native agent, Chapter 4.  
 
5.1.1.4 Extraction of FITC-BSA from PLGA Microcapsules 
Quantifying the amount of drug adsorbed is important for understanding the different 
parameters of the drug delivery experiments.  Quantifying loading, would identify the 
method with which the highest drug loading occurs.  It would also better explain the drug 
release profile, by providing a sense of how much drug is released in comparison to how 
much was initially adsorbed or was encapsulated.   
To determine 100% drug loading, an attempt to extract FITC-BSA from PLGA 
microcapsules was explored.  Briefly, PLGA microcapsules with adsorbed/encapsulated 
drug were suspended in 3mL of methylene chloride, 3mL of deionized water was added, 
and the suspension was vortexed.   The idea was that the polymeric microcapsule shell 
would dissolve in the methylene chloride, releasing the drug, which would then dissolve 
in the added water.  The fluorescence in the water was tested.  The method (repeated 6 
times) was concluded to be inefficient as it gave about 30% in variations between 
readings.  Variations between the readings could be a result of insufficient and 
inconsistent extraction of the FITC-BSA from the solvent phase into the water phase.    
For accurate and repeatable quantification, a radio labeled drug should be used.   
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5.1.1.5 Preliminary Incubation Study - Adsorption of 14-C-Paclitaxel on Phase II Agents  
As explained (Section 5.1.1.4) the use of fluorescently labeled drugs (FITC-BSA or 
doxorubicin) does not allow for the quantification of drug loading.  Shifting to a radio 
labeled drug was required.  The use of a clinically available anticancer drug was 
established to be a requirement in the selection process.  This led to the elimination of 
radio labeled BSA.  The use of radio labeled doxorubicin would have been ideal, 
however doxorubicin does not come radio labeled from the manufacturers.  It may be 
specially ordered from Sigma Chemical Co. (St. Louis, MO), but at a very high cost.  
Radio labeled (C-14) paclitaxel was found to be a more cost efficient option.   As seen by 
comparing Sections 2.3.1.1 and 2.3.1.2 doxorubicin and paclitaxel have one major 
difference, doxorubicin is a hydrophilic drug; and paclitaxel is a drug with some 
hydrophobic properties.  Due to this difference, previous experiments carried out with 
doxorubicin are expected to yield different results when repeated with Paclitaxel.  
Preliminary incubation experiments 14-C-Paclitaxel were carried out with Phase II 
agents (PLGA 50:50).  The protocol, calculations, results and discussion are presented 
below.  
  
Preparation of Stocks   
· C-14-Paclitaxel Stock: The 14-C-paclitaxel (10mCi with a specific activity of 
74mCi/mmol) was delivered in a small vial dissolved in 100mL of ethyl acetate. 
Methanol (950mL) was added to the vial contents and of the total 1.05mL volume 
was divided (40mL) into several small vials, which were stored in a -80°C freezer.    
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· Paclitaxel Stock: Paclitaxel (5mg) was dissolved in 5mL of methanol and divided 
(1mL) into 5 vials. 
· Incubation Stock: A 10mg/ml stock solution of 1:9, 14-C-Paclitaxel (10mL from 
C-14-Paclitaxel Stock): Paclitaxel (9mL from Paclitaxel Stock) was prepared, (the 
total volume was brought up to 1mL with PBS).   
 
Incubation experiments were carried out with deionized water and not with PBS in 
order to avoid issues associated with remaining salts from the PBS solution.  To 
determine optimal loading amounts with minimal initial burst effect, four samples were 
prepared, n=3 per sample.  Phase II agents were weighed (0.03g) and suspended in 10mL 
of deionized water.  Radio labeled paclitaxel, 50mL, 100mL, 200mL, and 300mL, from the 
incubation stock was added to each of the samples which were named, 17, 33, 67 and 
100, respectively.  The samples were incubated at 4°C for half an hour, then freeze dried.   
Three different quantification experiments were carried out, one to determine total 
amount adsorbed and un-adsorbed, one to determine adsorbed amount only, and one to 
determine un-adsorbed amount only.  To determine total amount, the dried incubated 
agent was weighed (approximately 0.005g, exact amounts recorded and final calculations 
normalized) in 20mL glass vials.  PBS (1mL) was added to each vial (the agent was well 
suspended) and cocktail fluid (Ultima Gold, for both aqueous and non aqueous samples) 
added (9mL), the vials were placed in the scintillation counter and radioactivity counted.  
To separately quantify adsorbed and un-adsorbed drug, the dried incubated agent was 
weighed (approximately 0.005g, exact amounts were recorded and final calculations were 
normalized) in 1.5mL centrifuge vials.  PBS (1mL) was added to each vial (the agent was 
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well suspended) and the suspension was centrifuged for 10 minutes on 10,000xg.  After 
centrifugation the supernatant (1mL), which contained the un-adsorbed drug, was 
carefully removed (by pipette) and placed in a 20mL glass vial, 9mL of cocktail fluid was 
added.  The vials were placed in the scintillation counter and radioactivity counted.  The 
adsorbed drug now remained on the settled agent (pellet) at the bottom of the 1.5mL 
centrifuge vial.  To extract and count the adsorbed drug, the agent was suspended in 
0.5mL of PBS.  The suspension was moved to a 20mL glass vial.  Another 0.5mL was 
added to the centrifuge vial, as a wash process, to pick up any remaining agent, the PBS 
wash was also added to the same 20mL glass vial.    Cocktail fluid (9mL) was added to 
the vials that were then placed in the scintillation counter for quantification of 
radioactivity.  
 
Calculations  
The following equations were used for calculating and converting from one unit to the 
next.  
· 1 Bq = 1dps 
· 1Curie = 3.7*1010 Bq 
· 1Bq = 60dpm 
 
Results and Discussion 
Quantified results are presented in Fig 5.5.  Ideally the adsorbed amount plus the un-
adsorbed amount should equal 100% of the total amount.  Results indicated that this was 
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not the case, with adsorbed plus un-adsorbed amounts equal to only 78%, 76%, 75% and 
60% of the total amounts, for samples 17, 33, 67 and 100, respectively.   
There may have been a loss of drug occurring somewhere in the process of pellet and 
supernatant transfer. Paclitaxel is a very sticky drug and perhaps it was sticking to the 
side of the plastics used in the process.  It is recommended for future experiments that the 
pipette tips and the centrifuge vials be washed after use, and the wash examined for 
radioactivity traces.   
The initial burst, (un-adsorbed) drug found in the supernatant, was 27%, 27%, 19% 
and 19% of the amount adsorbed, for sample sets 17, 33, 67 and 100, respectively.  
Ideally the initial burst should be at an absolute minimal (if not non existent).  Additional 
experimentation needs to be carried out to improve this process. 
Acoustic testing was performed on the dried incubated Phase II agent.  Results 
indicated that the incubation process did not affect the acoustic properties of this agent, 
giving up to 24 dB after 20 minutes of insonation at 5MHz (25°C).   
  
5.1.2 Future Work  
Preliminary drug adsorption (Section 5.1.1.1) and drug encapsulation (Section 
5.1.1.3) experiments showed promise for use of the developed contrast agent as a drug 
delivery vehicle.  The experiments demonstrated that the high frequency ultrasound 
(5MHz) and low frequency ultrasound 47 kHz, respectively) can be used to trigger drug 
delivery of adsorbed and encapsulated drug, respectively.   
Future work should be carried out to establish an optimized protocol for both 
adsorption and encapsulation methods.  Ideally, a system with minimal initial burst, 
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minimal release with stirring, and almost 100% release with insonation is desired.   
Protocols should be tested with both hydrophilic and hydrophobic drugs.  The 
experiments should be repeated with Phase II agents made of different polymers (PLGA 
50:50, 75:25, 85:15 and PLA).  Variable results are expected, as these polymers have 
very different properties, as explain in Chapter 4.   
The preliminary drug delivery experiments identify pH as a parameter that affects the 
drug loading process (Section 5.1.1.2).  This parameter should be tested when optimizing 
a drug loading and encapsulation protocol.  Additionally an efficient washing protocol 
must also be established to eliminate initial burst of the drug upon immediate suspension 
in an aqueous solution.  Different drug loading concentrations should be tested and 
correlated to the effects on which they will have on the agent’s acoustic enhancement 
properties. 
Different fabrication parameters should also be investigated to enhance delivery upon 
insonation.  One study [Wang et al., 1997] described that incorporation of IPM (isopropyl 
myristate) into 20mm PLGA microspheres by a solvent extraction/evaporation method, 
increased the release of paclitaxel from the microspheres in vitro.  As explained IPM 
changes the morphology of the microsphere matrix and forms a structure with many 
channels filled with IPM.  These channels provide a means through which the drug can 
quickly diffuse out of the microcapsules.   
It is recommended that encapsulation of Doxorubicin and its release with low 
frequency ultrasound from within Phase II agent be investigated.  It is expected that 
Doxorubicin may be encapsulated with in the water phase of the fabrication process, as 
previously described with BSA (Section 5.1.1.3).   
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Additionally it is recommended that Paclitaxel be encapsulated within Phase II 
agents.  Hydrophobic drugs such as Paclitaxel not only make their intravenous use 
problematic but also make it difficult to handle and poses challenges with respect to its 
incorporation into drug delivery systems.   Methods used for the encapsulation of water-
soluble BSA (Section 5.1.1.3) may need to be modified for the encapsulation of 
hydrophobic Paclitaxel.  In comparison with PVA, Vitamin E TPGS (a water soluble 
derivative of natural vitamin E) has shown to significantly improve encapsulation 
efficiency (up to 100%) of the Paclitaxel in PLGA nanospheres [Mu et al., 2002].   
It is hypothesized from results of the preliminary experiments that the encapsulation 
method (when optimized) will result in more drug loading than the adsorption method, as 
well as an immediate 100% drug delivery upon insonation.   
  
5.2 TARGETING OF THE PLGA CONTRAST AGENT 
 Thus far, a PLGA/PLA contrast agent has been developed and optimized.  The drug 
delivery capabilities have been investigated and preliminary studies have shown positive 
results.  The long-term objectives of this research include targeting these agents to tumor 
cells. To investigate this aspect, the agent’s surface properties were modified as to allow 
the agent to adhere to a specific site when intravenously injected, schematic 
representation of this phenomenon is shown in Fig. 5.6.   
 Previous, unrelated work was done in our laboratory to conjugate a peptide (YIGSR) 
to an alginate surface [Dhoot, 2002].  The peptide was covalently attached to the alginate 
surface by an amide bond between the carboxyl groups of the alginate and the amide 
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groups of the peptide.  The bond formation was achieved by use of a zero length cross 
linker, EDC ((1-ethyl-3,-3-Dimethylamino-Propyl) carbodiimide).   
Preliminary studies to attach a peptide to Phase I contrast agent (PLGA 50:50) were 
explored on the basis of these concepts.  The hypothesis was that the amine groups of the 
peptide would be covalently bound to the carboxyl groups of the contrast agent by the 
method explained above.     
 Preliminary experimentation for the attachment of Peptide (Gly-Arg-Gly-Asp-Ser 
(GRGDS)) conjugated - Phase I contrast agent to NB2a neuroblastoma cells were carried 
out and are explained next. 
 
5.2.1 Methods and Experimental Set-up 
 Protocols for peptide attachment to Phase I contrast agents, and attachment of the 
agent to cells were developed and are explained in this section.  
 
5.2.1.1 Peptide Attachment to Phase I Contrast Agent 
 The following calculations were carried out to preliminarily determine quantities of 
agent, EDC ((1-ethyl-3,-3-Dimethylamino-Propyl) carbodiimide), Sulfo-NHS (N-
Hydroxysulfosuccinimide), and peptide (GRGDS) to be used in the attachment 
experiment.   
· 1g of agent: 2.5 x 10-5 moles of polymer (based on a molecular weight of 
40,000g/mol), this approximated to 2.5 x 10-5 moles of carboxylic acid groups. 
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· EDS (1-ethyl-3,-3-Dimethylamino-Propyl) carbodiimide was added in a 1:1 mole 
ratio to carboxylic acid groups.  Therefore 2.5 x 10-5 moles of EDC were needed, 
(which was a weight calculation of 4.9275mg).  
· Sulfo-NHS (N-Hydroxysulfosuccinimide) was added in a 1:2 mole ratio to EDC. 
This resulted in the addition of 1.25 x 10-5 moles of Sulfo-NHS (this was a 
calculated weight amount of 1.4388mg).    
· Peptide (GRGDS) used was composed of 60% peptide and 40% salts and other 
contents.  Peptide (250mg) was weighed to give a total peptide amount of 150mg.   
 The freeze-dried Phase I agent was weighed (0.1g) and suspended in 10mL of buffer 
(0.1M MES, 0.3M NaCl, adjusted to pH 6.5), with EDC (5mg) and NHS (1.4mg).  The 
suspension was stirred for 15 minutes.  The peptide (150mg) was added to the suspension, 
which was stirred for an additional 24 hours.  The peptide coated agent was collected by 
centrifugation, and washed three times with deionized water.  The washed contrast agent 
was freeze dried.   
 
5.2.1.2 Cell Work 
 NB2a cells were cultured in 10cm diameter culture dishes in DMEM (without L-
glutamine) plus 10% FBS (fetal bovine serum) with 2mM L-glutamine.  Cells were 
incubated at 37°C and 5% CO2.  The medium was changed and the cells were split every 
three days. 
 The cell culture medium was removed and the cells were washed by careful addition 
and removal of HBSS (10mL) from the plated cells.  To detach the cells from the culture 
dishes, trypsin (3mL of 0.25%) was added and the cells were incubated for 3min.  
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Growth medium, 7mL (same as culture medium described above) was added to the 
culture dish.  The cell suspension was re-plated.  
 
5.2.1.3 Phase I Contrast Agent Targeted to Cells  
 After passage nine, the cell suspension was divided into 6 wells of a 6-well cell 
culture plate. Growth medium (1.5mL) was added to plates 1 and 2, which were labeled 
Control 1.  Growth medium with suspended Phase I agent (0.75mg) was added to plates 3 
and 4, which were labeled Control 2.  Growth medium with suspended peptide coated 
Phase I agent (0.75mg) was added to plates 5 and 6, which were labeled Experimental.  
The cells were incubated for 2 hours, after which they were washed with HBSS.  The 
incubation time was selected at random as a starting point and only for proof of concept.  
Ideally attachment should occur within minutes.    
 
5.2.2 Attachment Results 
 The washed cells were viewed under a microscope.  Control 1, consisted of cells 
only, and acted as the control to which all cells in Control 2 (with added Phase I agent) 
and Experimental (with added peptide coated Phase I agent) were compared.  Control 2, 
which consisted of unmodified Phase I agent, and acted as the control to which 
Experimental (with added peptide coated Phase I agent) was compared.  Visual 
observations indicated that unmodified Phase I agent attached to the cell culture dish and 
not to the cells, while peptide coated Phase I agent was not seen attached to the cell 
culture dish as extensively, additionally some of the microcapsules were seen on the 
cells.    
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 These preliminary studies were promising and established proof of concept for 
potential targeting of the polymeric contrast agent.  This method has been further 
investigated and results achieved have been positive [Lathia et al., 2003a].  This is 
ongoing research.  
 
5.3 FABRICATION OF NANO CAPSULES FOR POTENTIAL FABRICATION OF NANO 
IMAGING AGENTS 
  
 The potential of adapting the research presented in this thesis to nano size agents was 
considered.  These smaller size agents would be able to travel to places that micro size 
particles would not.  With respect to cancer, the nano scale agents may be able to pass the 
leaky vasculature that the micro size agents would not be able to pass.   
 Nano scale (without encapsulation of camphor or ammonium carbonate) PLGA 
particles were fabricated by established methods [Kwon, 2001].  Minor changes were 
made to this method. PVA was used as the stabilizer in place of DMAB (Didodecyl 
dimethyl ammonium bromide) since it was used to fabricate Native, Phase I and Phase II 
agents (DMAB produced smaller spheres then those made with PVA, [Kwon, 2001]).  
Acetone was used instead of propylene carbonate, again to maintain similarities with the 
micro agent protocols.  The dialysis step in the established protocol [Kwon, 2001] was 
omitted and the nanocapsules were collected by ultra centrifugation.  
 
 Dynamic static scattering analysis (90Plus Dynamic Light Scattering Apparatus, at 
wavelength 670 nm, Brookhaven Instrumentation Corporation, Holtsville, New York) 
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was performed to determine the size distribution of the lyophilized agent, Fig. 5.7.  The 
fabricated spheres had a mean diameter of 320nm.   
 Concepts to develop Phase I and Phase II contrast agents (Sections 3.2.2 and 3.2.3, 
respectively) have been applied to optimize the acoustic properties of these nanocapsules 
[Le et al., 2003; Wheatley et al., 2003].  This research is ongoing.   
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Figure 5.1: Schematic representation of encapsulated (A), attached (B) and adsorbed (C) 
bioactive compounds within hollow PLGA microcapsules  
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Figure 5.2: Drug release of adsorbed Doxorubicin from Native agent.  Control (not 
exposed to ultrasound) ¦ , Experimental (insonated at 5MHz) ? .   
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Figure 5.3: Scanning electron micrograph (SEM) of Native agent with (A) and without 
(B) BSA adsorbed on the surface.  Magnification at 6,000X. Size bar denotes 
1mm. 
A 
B 
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Figure 5.4:  Drug release of encapsulated BSA from within Native agent.  Control (not 
exposed to ultrasound) ¦ , Experimental (exposed to pulsed ultrasound at 
47kHz for 2sec on and 5 sec off) ? .  (n=3, ± standard error from the mean)
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Figure 5.5: Incubation results from preliminary adsorption study, of 14-C-paclitaxel on 
Phase II agents.   
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Figure 5.6:  Schematic representation of a surface modified PLGA contrast agent to 
include targeting molecules and be able to attach (via a lock and key 
phenomenon) to a specific site.   
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Figure 5.7:  Dynamic light scattering analysis of Native nanocapsules prepared with 
acetone. Mean size distribution of capsules 321nm.   
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 6. CONCLUSIONS AND RECOMMENDATIONS 
 
The PLGA/PLA ultrasound contrast agents that have been developed not only work well 
as imaging agents, giving enhancements of up to 24dB both in vitro and in vivo but have 
also shown potential for use as targeted drug delivery vehicles.  Research is currently 
underway for this realization.   
 
Additional future considerations and experimentations can be explored with the Phase II 
PLGA/PLA contrast agent that has been developed.   
· Phase II contrast agent is air-filled.  As explained in Chapter 1, encapsulation of a 
hydrophobic gas can prolong the stability of the agent.  Investigation of methods to 
replace air with a hydrophobic gas in the fabrication process of Phase II agent may 
further increase stability of the agent.   
· As evidenced by Lupron Depot (an FDA approved pharmaceutical, consisting of 
PLGA microcapsules, for the treatment of endometriosis), a small amount of 
methylene chloride remaining in a product is acceptable by the FDA, but only if the 
product benefits outweigh its safety concern.  A future consideration may be to find 
an alternate (safer) solvent to fabricate the contrast agent developed, as a precautious 
measure to avoid rejection of the product by the FDA.   
· Sterilization methods should also be explored.  Biodegradable poly esters are 
usually sterilized by ethylene oxide (ETO) because other procedures such as 
irradiation, heat, steam or acid, cause extensive alterations of the matrix, and  
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accelerate polymer degradation.  Use of RFGD plasma was investigated was also 
explored as an alternate sterilization method [Holy et al., 2001] 
 
The research carried out for this project can be used towards the development of an 
imaging and targeted therapeutic biodegradable system, for the treatment and diagnosis 
of cancer.  Once established, earlier detection of cancer treatment will be possible.  
Additionally the treatment process will be physically and psychologically better for the 
patient, as the healthy cells will be spared in the process.  It is a long road, but many 
researchers are hard at work for this realization.   
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 APPENDIX A. MATERIALS 
 
 
 
A list of materials used for experimentation described and discussed throughout this thesis are 
listed below.  
· Poly (D,L-lactide-co-glycolic acid 50:50, PLGA) (Resomer RG 504 H, lot 34020) was 
purchased from Boehringer Ingelheim Chemicals, Henley Division (Montvale, NJ)   
· Poly (D,L-lactide-co-glycolic acid 50:50, PLGA) (Medisorb 5050 DL 3A, 75:25 DL, 
85:15 DL, and 100 DL) were purchased from Alkermes, Inc. (Alkermes, Inc. OH). 
· Poly (vinyl alcohol) (PVA), 80% mole hydrolyzed with a Mw of 6000, 88% mole 
hydrolyzed with a Mw of 25000 and 99% mole hydrolyzed with a Mw of 133000 were from 
Polysciences, Inc.  
· (1R)-(+)-Camphor, EDC ((1-ethyl-3,-3-Dimethylamino-Propyl) carbodiimide), Gly-Arg-
Gly-Asp-Ser (GRGDS), Sulfo-NHS (N-Hydroxysulfosuccinimide), Antibioitics (penicillin 
and streptomycin), Doxorubicin, C-14-Paclitaxel, FITC-BSA, BSA and L-glutamine were 
from Sigma Chemical Co. (St. Louis, MO).  
· Ammonium Carbonate (NF-FCC grade) was from Mallinckrodt-Baker (Phillipsburg, NJ).  
· NB2a cells were a gift from Professor Thomas Shea at the University of Massachusetts 
(Lowell Campus). 
·  Dulbecco’s Modified Eagle Medium (DMEM), Hank’s Balanced Salt Solution (HBSS), 
Fetal Bovine Serum (FBS) and all solvents optima and reagent grade from Fisher Scientific 
(Fair Lawn, NJ). 
· Ultima Gold (high flash point LSC- cocktail fluid) was from Packard Instrument 
Company, Inc. (Perkin Elmer Life Sciences Inc., MA). 
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APPENDIX B. SUMMARIZED CONTRAST AGENT FABRICATION
Methylene 
Chloride
Put 10 mL of methylene 
chloride in a 50 mL beaker –
Place parafilm over the 
beaker, methylene chloride 
evaporates very quickly and 
changes in volume will alter 
microcapsule morphology
Add 1ml of 
Deionized 
water and 
probe sonicate 
for 30 seconds 
(to form W/O 
emulsion) 
Put 0.5g of PLGA in Methylene 
Chloride and stir until PLGA is 
fully dissolved
PLGA in Methylene
Chloride
Stir Plate
Pour W/O emulsion into 50 mL 
of a 5% PVA solution
(The PVA 
solution must        
be cold and 
preferably in 
a 400 ml 
beaker)
(To form 
W/O/W 
emulsion)
Homogenize 
for 5 
minutes at 
9,500rpm 
Pour 100 mL of 2% 
isopropanol solution 
into the foamy
W/O/W
emulsion and 
stir for 
one hour
Pour double emulsion into 4-6 50 mL 
centrifuge vials
Centrifuge for 5 min on 15,000 rpm
Carefully pour the supernatant out of 
each vial
Combine the pellet (capsules) into one vial
Bring up to 50 mL with deionized water
Centrifuge again for 5 min on 15,000 rpm
Carefully pour the water out of the vial
Wash the pellet with Hexane (3X)
Pipette off excess Hexane between each wash 
After the third wash pipette of excess hexane
Let the remainder of hexane evaporate off 
Bring up to 50 mL with Deionized water
Centrifuge for 5 min on 15,000 rpm
Carefully pour the water out of the vial 
Cover the vial with a kem wipe 
Place the vial in a -80°freezer until frozen
Freeze dry for at least 24 hours
A B 
 5,   
 5,000 rpm 
 -80°C  fr ezer until frozen 
Figure B1: Fabrication process of Native Agent (by a double emulsion 
process, encapsulating and later subliming water) 
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Put 10 mL of methylene 
chloride in a 50 mL beaker –
Place parafilm over the 
beaker, methylene chloride 
evaporates very quickly and 
changes in volume will alter 
microcapsule morphology
Pour W/O emulsion into 50 mL 
of a 5% PVA solution
(The PVA 
solution must        
be cold and 
preferably in 
a 400 ml 
beaker)
Put 0.5g of PLGA in 
Methylene Chloride and 
stir until PLGA is fully 
dissolved
Put 0.05g of camphor in
Methylene Chloride and stir 
until fully dissolved
THEN
(To form 
W/O/W 
emulsion)
Homogenize 
for 5 
minutes at 
9,500rpm 
Add 1ml of 
Deionized 
water and 
probe sonicate 
for 30 seconds 
(to form W/O 
emulsion) 
Pour 100 mL of 2% 
isopropanol solution 
into the foamy
W/O/W
emulsion and 
stir for 
one hour
Pour double emulsion into 4-6 50 mL 
centrifuge vials
Centrifuge for 5 min on 15,000 rpm
Carefully pour the supernatant out of 
each vial
Combine the pellet (capsules) into one vial
Bring up to 50 mL with deionized water
Centrifuge again for 5 min on 15,000 rpm
Carefully pour the water out of the vial
Wash the pellet with Hexane (3X)
Pipette off excess Hexane between each wash 
After the third wash pipette of excess hexane
Let the remainder of hexane evaporate off 
Bring up to 50 mL with Deionized water
Centrifuge for 5 min on 15,000 rpm
Carefully pour the water out of the vial 
Cover the vial with a kem wipe 
Place the vial in a -80°freezer until frozen
Freeze dry for at least 24 hours
Figure B.2: Fabrication process of Phase I agent (by a modified double emulsion 
process, encapsulating and later subliming water and camphor) 
A 
C 
B 
D E 
G F  
 
 
-80°C  freezer until frozen 
5,000 rpm 
5,0  rpm 
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Pour 100 mL of 2% 
isopropanol solution 
into the foamy
W/O/W
emulsion and 
stir for 
one hour
Pour double emulsion into 4-6 50 mL 
centrifuge vials
Centrifuge for 5 min on 15,000 rpm
Carefully pour the supernatant out of 
each vial
Combine the pellet (capsules) into one vial
Bring up to 50 mL with deionized water
Centrifuge again for 5 min on 15,000 rpm
Carefully pour the water out of the vial
Wash the pellet with Hexane (3X)
Pipette off excess Hexane between each wash 
After the third wash pipette of excess hexane
Let the remainder of hexane evaporate off 
Bring up to 50 mL with Deionized water
Centrifuge for 5 min on 15,000 rpm
Carefully pour the water out of the vial 
Cover the vial with a kem wipe 
Place the vial in a -80°freezer until frozen
Freeze dry for at least 24 hours
Put 10 mL of methylene 
chloride in a 50 mL beaker –
Place parafilm over the 
beaker, methylene chloride 
evaporates very quickly and 
changes in volume will alter 
microcapsule morphology
Pour W/O emulsion into 50 mL 
of a 5% PVA solution
(The PVA 
solution must        
be cold and 
preferably in 
a 400 ml 
beaker)
Put 0.5g of PLGA in 
methylene chloride and 
stir until PLGA is fully 
dissolved
Put 0.05g of camphor in 
methylene chloride and stir 
until fully dissolved
THEN
Add 1ml of 
4 w/v % 
ammonium 
carbonate 
solution
THEN
probe 
sonicate for 
30 seconds 
(to form 
W/O 
emulsion) 
(To form 
W/O/W 
emulsion)
Homogenize 
for 5 
minutes at 
9,500rpm 
Figure B.3: Fabrication process of Phase II agent (by a modified double emulsion 
process, encapsulating and later subliming water, camphor and  
ammonium carbonate) 
A 
C 
B 
D E 
G F  -80°C  freezer until frozen 
 
 
5,000 rpm 
5,0  rpm 
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APPENDIX C. STATISTICAL ANALYSIS 
 
 
 
 
Statistical analysis was performed using Statistica software (Tulsa OK, Statsoft, Inc.) and 
Microsoft Excel statistical functions.  
 
· Linear Regression: Explains the relationship with a straight-line fit to the data.  R-squared 
is a statistical measure of how well a regression line approximates real data points.  An r-
squared of 1.0 (100%) indicates a perfect fit.   
· ANOVA: Tests a hypothesis about means of multiple independent populations and 
assumes normally distributed populations with homogeneity of variance from which 
samples are independently sampled.  Turkey HSD (honestly significant difference) test 
was used to determine which means differ from which. 
· Standard Error of the Mean: Is an estimate of the standard deviation of the sampling 
distribution of means based on the data of one or more random samples.  
· Standard Deviation: Is the square root of the variance (a measure of how spread out a 
distribution is).  It is used to measure the dispersion among the measures in a given 
population.   
· T-Test: Asses whether the means of two groups are statistically different from each other.   
 
 
 
 
(Source: Taylor J.R., 1997) 
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APPENDIX D. ADDITIONAL DEFINITIONS RELATED TO ULTRASOUND 
 
 
 
 
Doppler Ultrasound 
Doppler ultrasound is based upon the Doppler effect [Fisher P., 1990]. When the object reflecting 
the ultrasound waves is moving, it changes the frequency of the echoes, creating a higher 
frequency if it is moving toward the probe and a lower frequency if it is moving away from the 
probe. How much the frequency is changed depends upon how fast the object is moving. Doppler 
ultrasound measures the change in frequency of the echoes to calculate how fast an object is 
moving.  
 
Power Doppler 
There are several forms of depiction of blood flow in medical Doppler imaging: color Doppler, 
pulsed Doppler, and power Doppler.  Power Doppler, which is not normally used in arterial 
Doppler evaluation of the lower extremity, shows the amplitude, or power, of Doppler signals 
rather than the frequency shift. This allows detection of a larger range of Doppler shifts and thus 
enhanced visualization of small vessels, (this is however at the expense of directional and 
velocity information.  
 
Abdominal Scan 
An abdominal ultrasound looks at the gallbladder, bile ducts, kidneys, liver, pancreas, and spleen. 
It also includes a view of the aorta and retroperitoneum. 
 
 
  
185 
 
Acoustic Cavitation 
Acoustic cavitation is defined as the formation, growth, and impolsive collapse of 
bubbles in liquids irradiated with high-frequency ultrasound [Suslick et al, 1999]  
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